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V. Summary 
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of 
unknown origin, characterised by alveolar epithelial cell damage, increased deposition of 
extracellular matrix (ECM) in the lung interstitium, enhanced fibroblast/myofibroblast 
proliferation and activation, which ultimately leads to the distortion of normal lung 
architecture and loss of respiratory function. The interstitial fibroblast/myofibroblast 
represents the key effector cell responsible for the increased ECM deposition 
characteristic of IPF. Fibroblasts secrete large amounts of fibrillar collagens, which are 
the key ECM proteins, which exhibit elevated expression in this disease. The TGF-β is 
the primary and most potent profibrotic mediator involved in fibroblast activation and 
differentiation, and subsequent collagen production and deposition. Thus, it was 
hypothesised that the expression of TGF-β system components is altered in IPF, 
ultimately affecting the fibroblast activation and collagen synthesis. 
In this study, the expression levels of ALK1, ALK5, TGF-βRII and endoglin, as 
well as Smads and TGF-β target genes, were analysed in the context of human 
pulmonary fibrosis. The expression of ALK1 was significantly downregulated in human 
lung homogenates from fibrotic lungs when compared to those from healthy subjects. 
Expression of other TGF-β system components was not altered in the disease. 
Furthermore, ALK1 and ALK5 mRNA and protein expression was localised to epithelial 
cells, endothelial cells, smooth muscle cells and fibroblasts, and the expression of ALK1 
and ALK5 was decreased in primary fibroblasts isolated from human fibrotic lung tissue, 
compared to healthy controls, as assessed by quantitative RT-PCR and 
immunohistochemistry. The human fibroblast cell lines HFL1 and IMR-90 were selected 
for functional assays because these cell lines express TGF-β system components, and 
demonstrate active TGF-β and BMP signalling characterised by the phosphorylation of 
Smad2/3 and Smad1/5/8, respectively. Finally, treatment of human lung fibroblast cell 
lines with the siRNA specific for ALK1 attenuated collagen deposition, which was rescued 
by TGF-β1 stimulation. However, the impact of ALK1 on fibroblast activation and collagen 
deposition may not be primary, as the other signalling pathways might be involved. 
These results demonstrated that ALK1 was expressed and functional in lung 
fibroblasts. The lack of ALK1 might be involved in the activation of fibroblasts thus 
leading to the collagen production, therefore being involved in the pathogenesis of 
pulmonary fibrosis. 
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VI. Zusammenfassung 
Die idiopathische pulmonale Fibrose (IPF) ist eine fortschreitende und tödlich 
verlaufende Lungenerkrankung mit unbekanntem Ursprung, charakterisiert durch 
geschädigte Alveolarepithelzellen, gesteigerte Ablagerung von extrazellulärer Matrix 
(ECM) im Lungeninterstitium, erhöhte Fibroblasten/Myofibroblastenproliferation und         
-aktivierung, welche letztendlich zu einer Verformung der normalen Lungenstruktur und 
dem Verlust der respiratorischen Funktion führt. Der interstitielle Fibroblast/Myofibroblast 
repräsentiert die Schlüsseleffektorzelle, welche für die gesteigerte ECM-Ablagerung 
verantwortlich ist und somit charakteristisch für eine IPF. Fibroblasten sekretieren große 
Mengen von fibrillären Kollagenen, welche die Schlüsselproteine der ECM sind, was 
auch durch ihre gesteigerte Expression in dieser Erkrankung belegt wird. TGF-β ist der 
primäre und stärkste profibrotische Mediator, der an der Fibroblastenaktivierung und 
Differenzierung sowie der anschließenden Kollagenproduktion und Ablagerung beteiligt 
ist. Folglich war anzunehmen, dass die Expression von TGF-β Komponenten in IPF 
verändert ist, letztlich wirken Fibroblastenaktivierung und Kollagensynthese. 
In dieser Studie wurde das Expressionsniveau von ALK1, ALK5, TGF-βRII und 
Endoglin, ebenso wie das der Smads und TGF-β Zielgene im Zusammenhang mit der 
humanen pulmonalen Fibrose untersucht. Die Expression von ALK1 war in humanen 
Lungenhomogenaten von fibrotischen Lungen im Vergleich zu gesunden Lungen 
signifikant herunterreguliert. Die Expression von anderen TGF-β Komponenten  war in 
dieser Krankheit unverändert. Darüber hinaus war die ALK1 und ALK5 mRNA und 
Proteinexpression in Epithelzellen, Endothelzellen, glatten Muskelzellen und Fibroblasten 
lokalisiert. Die Expression von ALK1 und ALK5, die mit Hilfe quantitativer RT-PCR und 
Immunhistochemie ermittelt wurde, war in primären Fibroblasten, welche aus humanem 
fibrotischen Lungengewebe isoliert  wurden, im Vergleich zu gesunden Kontrollen 
geringer. Für funktionelle Untersuchungen wurden die humanen Fibroblastenzelllinien 
HFL1 und IMR-90 ausgewählt, da diese Zelllinien Komponenten des TGF-β Signalweges 
exprimieren und aktive TGF-β und BMP Signaltransduktion, charakterisiert durch die 
jeweilige Phosphorylierung von Smad2/3 und Smad1/5/8, aufzeigen. Die Behandlung von 
humanen pulmonalen Fibroblastenzelllinien mit der spezifischen siRNA für ALK1 
verringerte die Kollagenablagerung, welche durch eine TGF- β Stimulation hervorgerufen 
wurde. Dennoch dürfte der Einfluss von ALK1 auf die Fibroblastenaktivierung und 
Kollagenablagerung nicht der wichtigste sein, da auch andere Signalwege involviert sein 
könnten. 
Zusammenfassung  XII 
Diese Ergebnisse zeigten, dass ALK1 in Lungenfibroblasten exprimiert wird und 
funktionell ist. Ein Mangel von ALK1 könnte in die Fibroblastenaktivierung involviert sein 
und dadurch zur Kollagenproduktion führen, demzufolge kann ALK1 an der Pathogenese  
der pulmonalen Fibrose beteiligt sein.  
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1. Introduction 
1.1. Idiopathic pulmonary fibrosis 
1.1.1. Characteristics of idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown cause, generally 
with a chronic, progressive and irreversible course and often with a fatal outcome 1. 
Despite extensive research efforts over the past decades, no currently available therapy 
has been demonstrated to prevent or reverse the progression of this disease 2. In 
principal, IPF is characterised by alveolar epithelial cell damage, increased deposition of 
extracellular matrix (ECM) in the lung interstitium, and enhanced fibroblast/myofibroblast 
proliferation and activation. These processes ultimately lead to distortion of normal lung 
architecture and loss of respiratory function 3.  
Idiopathic pulmonary fibrosis is the most common form of idiopathic interstitial 
pneumonia (IIP), which constitutes a group of diffuse parenchymal lung diseases 
(DPLDs) also described as interstitial lung diseases. The IIPs include the entities of IPF, 
also referred to as cryptogenic fibrosing alveolitis (CFA), nonspecific interstitial 
pneumonia (NSIP), cryptogenic organising pneumonia (COP), acute interstitial 
pneumonia (AIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), 
desquamative interstitial pneumonia (DIP), and lymphocytic interstitial pneumonia (LIP) 4.  
Idiopathic pulmonary fibrosis is a rare disease that affects approximately five 
million people worldwide. Idiopathic pulmonary fibrosis does not favour particular race, 
ethnic group or social environment. The incidence of IPF increases with age. The mean 
age at presentation is 66 years. Occurrence of IPF is very rare in children 5. The medium 
survival is two to five years from the time of diagnosis. Although IPF affects millions of 
individuals worldwide, there is still no effective therapeutic approach, and so far, lung 
transplantation is the only viable option for patients that are refractory to medical therapy. 
Multiple lines of evidence suggest that genetic factors could impact the 
development of lung fibrosis 6. Familial pulmonary fibrosis (FPF), also termed as familial 
interstitial pneumonia and familial idiopathic pulmonary fibrosis, is referred to those cases 
when two or more members of a family have an idiopathic interstitial pneumonia 7. 
Clinical features of FPF are indistinguishable from those of the sporadic form, except for 
an earlier age of onset. Familial IPF accounts for 0.5 to 2% of all cases of IPF 5. The 
largest description of FPF identified 111 families with 309 affected family members 8.  
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Since the pathogenesis of IPF is complex and poorly understood, identification of 
risk factors that may contribute to the development of the disease is essential. Although 
cigarette smoking 9, the presence of several viruses 10-12, and environmental factors 5, 9, 12 
have been suggested to increase the risk of developing IPF, their impact remains to be 
fully elucidated.  
The term “idiopathic” suggests that there are no known causes of IPF. Diagnostic 
criteria for IPF require exclusion of known causes of interstitial lung diseases 5, therefore, 
advances in cellular and molecular biology have extended our understanding of the 
biological processes involved in the initiation and progression of this disease. 
 
 
1.1.2. Histopathological changes in idiopathic pulmonary 
fibrosis 
Idiopathic pulmonary fibrosis is associated with the pathologic pattern known as 
usual interstitial pneumonia (UIP), and therefore, is also referred to as IPF/UIP 5. The 
histological hallmark is a heterogeneous appearance with alternating areas of normal 
lung with interstitial inflammation and fibrosis in early stages, and honeycomb change in 
the later stages of the disease process (Figure 1.1.). These changes are worse in the 
lower lobes and often seen in subpleural, peripheral and paraseptal areas 4. Inflammatory 
components observed in the lungs of patients with IPF typically consist of lymphocytes 
and plasma cells, and to some extent eosinophils and neutrophils. Fibroblast foci, 
representing the sites of acute lung injury, are located within the interstitial space directly 
beneath alveolar epithelium and at the interphase between collogenised and normal-
appearing lung. Moreover, alveolar epithelial cell (AEC) injury with hyperplasia of type II 
pneumocytes is an early and consistent finding in IPF. Reduced proliferative capacity, 
increased apoptosis, an inability to differentiate into type I AECs, and ineffective 
migration of type II AECs have also been observed in pulmonary fibrosis. The 
accumulation of ECM proteins, such as collagens, fibronectin, proteoglycans, and elastin, 
has been considered as hallmark of fibrosis 2, 13, 14. The dense fibrosis causes remodelling 
of the lung architecture, resulting in collapse of alveolar walls followed by the loss of 
respiratory function 4 . 
Introduction  3 
 
Figure 1.1. Histopathological changes in the lung in IPF. 
Low-magnification photomicrograph of IPF illustrating heterogeneous involvement of the 
parenchyma. Zones of interstitial fibrosis are seen alternating with areas of normal lung. Original 
magnification is ×40 (a). Higher-magnification demonstrates enlarged cystic airspaces lined with 
hyperplastic alveolar epithelium (arrowheads). Beneath the mucosal layer is an advancing region 
of young fibrosis containing loose extracellular matrix (pale pink staining) and fibroblasts (arrow). 
Original magnification is ×200 (b) 
5
.  
 
 
1.1.3. Pathogenesis of idiopathic pulmonary fibrosis 
Current explanations of the pathogenesis of IPF are controversial, and ongoing 
research continues to investigate multiple hypotheses. From these attempts, two main 
hypotheses of IPF pathogenesis have arisen. The first one is the “inflammatory model of 
IPF pathogenesis” and the second is recognised as “epithelial/fibroblastic model”.  
According to the first hypothesis, IPF has been long considered as the deleterious 
consequence of an unresolved chronic inflammatory process that follows an 
unrecognised insult 3, and injures the lung and modulates lung fibrogenesis, leading to 
the end-stage fibrotic scar. This hypothesis is based on the idea that injury/inflammation 
of the alveolar-capillary constituents and basement membrane leads to the loss of type I 
epithelial and endothelial cells, the proliferation of type II pneumocytes, the loss of 
alveolar space integrity, the recruitment and proliferation of stromal cells, and the 
deposition of the ECM 15. However, there is little evidence that inflammation is prominent 
in early disease, and it is unclear whether inflammation is relevant to the development of 
the fibrotic process. Evidence suggests that inflammation does not play a pivotal role as 
most patients with IPF do not respond to anti-inflammatory drugs 4. Thus, the chronic 
process of fibrosis may be separated from the acute process of inflammation, and 
inflammation appears necessary but not sufficient to explain the pathophysiology of 
fibrosis 16.  
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It has been suggested that IPF is characterised by a sequence of events that start 
with alveolar epithelial micro-injuries followed by the formation of fibroblastic foci and 
result in an exaggerated deposition of ECM, which drives the destruction of the lung 
parenchyma architecture 3. The primary sites of ongoing injury and repair are the regions 
of fibroblastic proliferation, so-called fibroblastic foci. These small aggregates of actively 
proliferating and secreting fibroblasts/myofibroblasts constitute multiple sites of alveolar 
epithelial injury with exuberant deposition of ECM. The alveolar epithelium exhibits a 
marked loss of, or damage to, type I cells, and hyperplasia of type II cells. Alveolar 
epithelial cells express several enzymes, cytokines and growth factors, like for instance, 
that may promote fibroblast migration and proliferation, their differentiation to 
myofibroblasts. Subsequently, myofibroblasts may provoke basement membrane 
disruption and alveolar epithelial cell apoptosis, leading to the inappropriate 
reepithelialisation. The result is the excessive deposition of ECM with the destruction of 
alveolar-capillary units and progression to dense fibrosis with loss of lung function 3, 4, 17-
19.  
 
 
1.1.4. Fibroblasts - key effector cells in IPF 
Fibroblasts are the most versatile of the connective-tissue cell family and possess 
a remarkable capacity to undergo various phenotypic conversations between distinct but 
related cell types. Fibroblasts participate in repair and regenerative processes in almost 
every human tissue and organ. Their primary function is to secrete ECM proteins that 
provide a tissue scaffold for normal repair events such as epithelial cell migration. 
Eventual dissolution of this scaffold and apoptosis of fibroblasts/myofibroblasts are critical 
for restoration of normal tissue architecture 20.  
In the normal adult lung, fibroblasts are present in the adventitia of vascular 
structures and airways. They are commonly cultured as adherent cells exhibiting spindle-
shape morphology and expressing interstitial collagens (type I and III), but they do not 
express markers of other differentiated cell types, therefore, there is the relative lack of 
specific marker to indicate the purity of isolated population 21. The interstitial fibroblasts 
comprise 30-40% of the cells in the normal adult human lung.  
Although fibroblasts in the normal lung synthesise very little matrix, activated 
myofibroblasts are major contributors to fibrotic lung disease (Figure 1.2.). These 
mesenchymal cells represent foci of organising acute lung injury and actively ongoing 
fibrogenic process, and they are considered as the key player, that is able to transform a 
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potentially reversible disorder to a progressive and irreversible one 18. Myofibroblasts 
possess ultrastructural features intermediate between fibroblasts and smooth muscle 
cells. They are identified by the expression of α-smooth muscle actin (α-SMA).  
The origin of pathological fibroblast foci within the IPF lesion remains puzzling. 
Possibilities include differentiation of resident fibroblasts 21, recruitment of circulating 
fibroblast precursors (fibrocytes) 22-24 and transdifferentiation of epithelial cells into 
pathological fibroblast phenotypes during the process called epithelial-to-mesenchymal 
transition (EMT) 25, 25-28.  
The factors regulating activation and differentiation of myofibroblasts are poorly 
understood, although the importance of transforming growth factor (TGF)-β in this process 
has been widely appreciated 29. Moreover, myofibroblasts are characterised by the 
production and secretion of collagen and a variety of cytokines, including the profibrotic 
TGF-β1 17. Thus, the well-known effect of TGF-β on α-SMA expression and 
myofibroblasts differentiation suggest the importance of the canonical TGF-β-associated 
Smad pathway. In vitro evidence indicates the importance of Smad3 in α-SMA expression 
in lung fibroblasts, and Smad3 deficiency in vivo results in a significant reduction in 
pulmonary fibrosis 30, 31.  
Fibroblasts from the lungs of IPF patients produce a number of ECM proteins and 
integrin molecules. This is accompanied by an imbalance in the production of matrix 
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). The 
expression of the four TIMPs is demonstrated to be higher in the interstitium, where ECM 
accumulates, suggesting that a nondegrading fibrillar collagen microenvironment is 
present in pulmonary fibrosis. For instance, notable expression of TIMP-2 in the 
fibroblastic foci may be related to longer survival of myofibroblasts since in addition to its 
MMP inhibitory function it is also able to induce proliferation 20, 32-34.  
Regarding the contribution of fibroblasts/myofibroblasts to the abnormal alveolar 
reepithelialisation, it has been demonstrated that fibroblasts from the lungs of IPF patients 
produce angiotensin peptides able to induce epithelial cell death in vitro, which also 
probably occurs in vivo. In addition, myofibroblasts from the lungs of IPF patients 
synthesise gelatinases A (MMP-2) and B (MMP-9), two matrix MMPs that degrade 
basement membrane molecules, contributing to the failure of the repair of alveolar type I 
epithelial cells and enhancing the migration of fibroblasts/myofibroblasts into the alveolar 
space 18, 20, 33.  
Myofibroblasts at various states of development and activation express high or 
low levels of the cell surface marker thymus cell antigen (Thy)-1. Rat fibroblasts with high 
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levels of Thy-1 show a less contractile phenotype and α-SMA expression than Thy-1-low 
fibroblasts 35. Similar phenotypic differences are found in humans, with the fibroblastic foci 
characteristic of IPF containing a fibroblast population whose Thy-1 expression level is far 
lower that the rest of the lung 36. Whether Thy-1 expression causes or results from 
fibroblastic foci formation, as well as the relevance of this finding to the pathogenesis of 
IPF, are questions that have yet to be answered 29.  
 
 
 
Figure 1.2. Subepithelial fibroblastic foci in lungs of patients with IPF. 
Fibroblasts foci are indicated by arrows. Hematoxylin and eosin staining; original magnification is 
×200. 
17, 18
 
 
 
1.1.5. Collagen - a key component of the extracellular matrix  
Extracellular matrix remodelling is a dynamic process involved in development, 
fibrosis, tissue repair, tumor progression and metastasis. Under physiological conditions 
this process is tightly controlled. Disturbances either in the synthesis or in the 
degradation of the ECM result in an accumulation of ECM, primarily of fibril-forming 
collagens, which has been linked to the aberrant remodelling characteristics of lung 
fibrosis. The fibrotic lung contains approximately two to three times more ECM than 
normal lung, including collagens I, III, V, VI and VII, fibronectin, elastin, and 
proteoglycans. Proteases (MMPs) and their inhibitors play an important role in both, the 
degradation of ECM proteins as well in the activation and regulation of the processes that 
underlie their deposition 37, 38. Two subtypes of type I collagen, COL1A1 and COL1A2, 
are the major collagens synthesised during abnormal wound repair, and their expression 
is regulated by TGF-β1 39.  
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 Collagens are abundant proteins and typically represent 25% of the total protein 
content of mammals. Currently, there are 28 collagen molecules, which are grouped in 
subfamilies depending on their structure and function. Collagen fibrils are the key ECM 
proteins that display significantly increased levels in IPF. The fibrils are synthesised and 
secreted by fibroblasts, but how this process is controlled during regeneration and tissue 
repair remains poorly understood. Collagens are trimeric molecules in which each chain 
consists of repeating Gly-X-Y triplets, where X and Y are usually proline and 
hydroxyproline, respectively. This triplet motif results in a left-handed helix that, together 
with two other helices, can form a right-handed triple-helical structure that (dependent on 
collagen type) can be homotrimeric or heterotrimeric.  
Biosynthesis of collagen is a complex process that requires the formation of 
procollagen, which undergoes extensive post-translational modification. These 
modifications occur prior to triple helix formation, and consist of hydroxylation of proline 
and lysine. Hydroxylation of L-proline occurs in an ascorbic acid-dependent manner and 
is essential for collagen stability 38, 40.  
 
 
 
 
1.2. Transforming growth factor (TGF)-β signalling 
In the late 1970s and early 1980s, it was discovered that polypeptides secreted by 
Moloney sarcoma virus-infected mouse 3T3 cells exhibited the ability to confer a 
“transformed” phenotype to non-neoplastic cells, such as rat NRK fibroblasts. In 1983, 
this transforming activity could be assigned to a combination of two entirely different 
polypeptides, termed transforming growth factor (TGF)-α and TGF-β. Transforming 
growth factor α was identified to be an analogue of epidermal growth factor (EGF), while 
TGF-β represented a novel growth factor completely unrelated to any known polypeptide 
at the time. The name “transforming growth factor” was thus designed in the context of 
this observation. This original nomenclature, however, is misleading, as TGF-β elicits 
very potent tumor suppressor and antiproliferative activities, especially on epithelial cells. 
Today, TGF-β represents the prototypic member of a large and still growing family of 
secreted polypeptide growth factors that exerts pleiotropic effects on many cell types. 
Transforming growth factor β plays essential roles in embryonic development and cellular 
differentiation, regulate cellular proliferation and cell death, induce ECM synthesis, and 
modulate the immune response 41, 42. Human genome contains 28 genes that encode 
Introduction  8 
members of this family. The ligands, receptors and their intracellular effectors, the 
Smads, are conserved in eukaryotes from Caenorhabditis elegans and Drosophila to 
mammals 43. 
 
 
1.2.1. The TGF-β ligands 
More than 60 TGF-β family members have been identified in multicellular 
organisms (Figure 1.3.). Among these, there are many multifunctional cytokines including 
TGF-βs, activins, inhibins, anti-Müllerian hormone (AMH), bone morphogenetic proteins 
(BMPs), myostatin, Müllerin inhibiting substance (MIS), growth and differentiation factors 
(GDFs), Nodal, Vg1 and others 44, 45. Three isoforms of TGF-β, termed TGF-β1, -β2 and   
-β3, are present in mammals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic relationship between TGF-β superfamily members in vertebrates. 
The downstream R-Smads 1, 2, 3, 5 and 8 are grouped based on their signalling specificity. 
Commonly used alternative names are: ALK2/ActRI, ALK3/BMPRIA, ALK4/ActRIB, ALK5/TβRI, 
and ALK6/BMPRIB 
45
.  
 
 
Transforming growth factor-β is secreted predominantly as a latent complex that 
must be activated before being capable of eliciting biological effects. The three isoforms 
of TGF-β are secreted as latent precursor molecules (L-TGF-β) that contain an amino-
terminal hydrophobic signal peptide region, the latency associated peptide (LAP) region 
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and the carboxyl-terminal potentially bioactive region. The L-TGF-β is complexed with 
latent TGF-β-binding protein (LTBP), requiring activation into a mature form for receptor 
binding and activation of signal transduction pathways. The LTBP is removed 
extracellularly either by proteolytic cleavage by proteases such as plasmin, or through the 
action of binding proteins, such as thrombospondin 46, 47. After proteolytic cleavage of the 
mature carboxyl-terminal part, biologically active TGF-β proteins are generated.  
 
 
1.2.2. The TGF-β receptors 
Transforming growth factor β superfamily members bind to three types of TGF-β 
receptors, which are classified as the type I (53 kDa), type II (73-95 kDa) and type III (110 
kDa) receptors, depending on their molecular masses. The type I and type II receptors 
contain serine/threonine kinase domains, whereas the type III receptors lack a 
cytoplasmic kinase domain. This suggests that the type III receptors may serve as 
accessory receptors promoting ligand access to the signalling receptors. All members of 
these subgroups share structural and functional similarities within their own subgroups 48. 
Generally, type I and II receptors are glycoproteins with core polypeptides of 500 to 570 
amino acids including the signal sequence. They contain a cystein-rich extracellular 
domain, a short transmembrane helix and a cytoplasmic serine/threonine kinase domain 
(Figure 1.4.).  
The extracellular region is relatively short (approximately 150 aa), N-glycosylated, 
and contains 10 or more cysteine residues that may determine the general fold of this 
region. The transmembrane region and cytoplasmic juxtamembrane region of type I and 
II receptors have no singular structural features. However, the GS domain, the highly 
conserved 30-amino acid region immediately preceding the kinase domain, is a unique 
feature of type I receptors. This region is called GS domain because of a characteristic 
SGSGSG sequence it contains. Ligand-induced phosphorylation of the serines and 
threonines in the TTSGSGSG sequence of TGF-βRI by the type II receptor is required for 
activation of signalling. The GS domain is a key regulatory part of that may control the 
catalytic activity of type I receptor kinase. The kinase domain consists of the canonical 
sequence of a serine/threonine protein kinase domain. Transforming growth factor  
receptor type I have been shown to phosphorylate their substrates – Smad proteins – on 
serine residues, whereas TGF-β type II receptors autophosphorylate themselves and 
transphosphorylate type I receptors on serine and threonine residues 49. 
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Figure 1.4. The structure of the TGF-β type I (ALK1 and ALK5) and type II (TGF-βRII) 
receptors. 
There is homology between TGF-β types I receptors, which possess the specific GS domain, not 
present in type II receptors. The constitutively active type II receptor phosphorylates and activates 
type I receptors in their GS domain. 
 
 
 The receptor serine/threonine kinase family in the human genome comprises 12 
members – seven type I and five type II receptors – all dedicated to TGF-β signalling. 
The following receptors are ranked amongst the TGF-β type I receptors: 
 ALK1 (ACVRL1) for TGF-β ligands, 
 ALK2 (ActRI) for activins, BMP2 and BMP4 ligands, 
 ALK3 (BMPRIA) for BMP ligands, 
 ALK4 (ActRIB) for activins and TGF-β ligands, 
 ALK5 (TGF-βRI) for activins and TGF-β ligands, 
 ALK6 (BMPRIB) for BMP ligands, 
 ALK7 for Nodal, GDFs and Vg1 ligands. 
The following receptors are ranked amongst type II receptors: 
 TGF-βRII for TGF-β ligands,  
 ActRII for activins, BMP2, 4, 7, 
 ActRIIB for activins, BMP2, 4, 7, 
 BMPRII for BMPs, 
 AMHRII for anti-Müllerian hormone.  
There are two TGF-β type III receptors known as betaglycan (TGF-βRIII) and 
endoglin (CD105). The evidence suggests that accessory receptors do not have any 
The signal peptide 
sequence  
The extracellular domain  
The transmembrane domain  
The cytoplasmic tail  
(C-terminal extention) 
 
The GS domain 
 
 
The serine/threonine kinase domain 
aa 1 23 119 140 440 502 
aa 1 24 125 147 495 503 
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ALK1 
 
ALK5 
 
TGF-βRII 
Introduction  11 
intrinsic signalling function, some of these molecules act as supplementary receptors hat 
assist the type I and II subgroups for ligand binding, and potentiate the signalling 
cascade, other function as inhibitors of the signalling pathway 49-51. 
 
 
1.2.3. The Smad proteins 
Smad proteins function as signal transducers of TGF-β family members and they 
are the first identified substrates of type I receptor kinases. The name Smad originates 
from a fusion between Drosophila mothers against dpp (Mad) and C. elegans Sma 52, 53.  
Based on structural and functional considerations, eight members of the Smad 
family have been identified which can be further classified into three distinct subfamilies: 
 Smads that are direct substrates of TGF-β family receptor kinases, the receptor-
activated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5, Smad8), 
 Smads that participate in signalling by associating with these receptor-regulated 
Smads, the common-mediator Smads (Co-Smads: Smad4 and Smad4β ), 
 Antagonistic Smads that inhibit the signalling function of the other two groups, the 
inhibitory Smads (I-Smads: Smad6 and Smad7) (Fig. 1.5.). 
The subfamily of R-Smads can be further divided into 2 groups: 
 BMP-Smads, being activated in the BMP signalling pathway and phosphorylated 
by BMP type I receptors (Smad1, Smad5, and Smad8), 
 TGF-β/activin-Smads, activated and phosphorylated by TGF-β type I receptors 
and activin type I receptors (Smad2 and Smad3). 
The overall structure of R-Smads and Co-Smads comprises the highly conserved 
N-terminal Mad homology 1 (MH1) and the C-terminal Mad homology 2 (MH2) domains 
which form globular structures and are linked by a divergent proline-rich region of variable 
length. The I-Smads likewise contain the conserved MH2 domain but show very little 
similarity to other Smads in their N-terminal part 54. The R-Smads have a unique SSXS 
motif at the C-terminus, which is directly phosphorylated by activated TGF-β type I 
receptor on at least two serine residues 55. Co-Smads have both types of MH domains 
but TGF-β type I receptor is unable to phosphorylate this class of proteins since they do 
not have SSXS phosphorylation motif at the C-terminus. The MH1 domain of R-Smads 
and Co-Smads, except for Smad2, can bind to the specific DNA sequences. The MH2 
domains of R-Smads and Co-Smads are indispensable for homomeric and heteromeric 
complex formation. The L3 loop in the MH2 domain of R-Smads determine the specificity 
of the interaction with type I receptors 49, 52, 54, 56. 
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 Smad proteins do not contain any intrinsic enzymatic activity but rather exert their 
function through protein-DNA and protein-protein interactions via their MH1 and MH2 
domains. These domains of R-Smads have intrinsic affinity for each other and inhibit 
each other’s functions. The R-Smads are present predominantly as monomers in the 
steady state. Ligand stimulation promotes R-Smads to form homo-oligomers or hetero-
oligomers that are composed of R-Smads alone or together with Co-Smads. The 
phosphorylation of R-Smads allows them to interact with DNA and other proteins in the 
nucleus. The binding of Smads to DNA occurs with rather low affinity and sequence 
specificity. Therefore, Smads need to cooperate with each other and/or with other DNA-
binding proteins to regulate TGF-β target gene transcription 52, 57-60.  
 The I-Smads interact efficiently with the activated type I receptor, thereby 
preventing access of R-Smads to the activated type I receptor. Whereas Smad6 appears 
to preferentially inhibit BMP signalling, Smad7 acts as a general inhibitor of TGF-β 
signalling 52. 
 
 
1.2.4. The TGF-β signalling pathway 
In the current model of TGF-β signal transduction, biological effects of TGF-β are 
induced after binding of active TGF-β ligand to the ligand binding serine/threonine kinase 
receptor type II. The TGF-βRII has intrinsic kinase activity. The TGF-βRI is then recruited 
into a heterotetrameric receptor complex and phosphorylated in its GS domain by TGF    
-βRII, leading to activation of its kinase activity and subsequent intracellular signalling into 
the nucleus. This occurs predominantly by phosphorylation of cytoplasmic mediators 
belonging to the Smad proteins family. Type I receptors specifically recognise and 
phosphorylate the ligand-specific receptor-activated Smads (R-Smads). Upon 
phosphorylation, R-Smads form heteromeric complexes with common Smad, such as 
Smad4. These complexes are translocated into the nucleus, where they function as 
transcription factors, binding DNA either directly or in association with other DNA binding 
proteins (Figure 1.5.) 61, 62.  
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Figure 1.5. TGF-β signal transduction.  
Transforming growth factor β signal transduction is initiated by binding of TGF-β ligand to TGF      
-βRII. The TGF-βRI is then recruited into the receptor complex, in which the type I receptor, after 
having being phosphorylated, recruits and phosphorylates Smad2/3 molecules. These molecules 
form dimers with Smad4 and the heterodimer complex is translocated into the nucleus, where it 
activates or represses target gene transcription together with other cofactors 
62
.  
 
 
1.2.5. The role of TGF-β in idiopathic pulmonary fibrosis 
Transforming growth factor β is a multifaceted cytokine produced by several cell 
types, such endothelial cells, vascular smooth muscle cells, myofibroblasts, macrophages 
and other haematopoietic cells. Transforming growth factor β is involved in the 
modulation of a wide array of biological processes including cell growth and 
differentiation, cell adhesion, cell migration, cell apoptosis, ECM production, immune 
response, embryonic development, and wound healing 63. Transforming growth factor β 
plays a pivotal role in the fibroproliferative changes that follow tissue damage in many 
vital organs and tissues, including liver 64, 65, lung 5, kidney 66, skin 47, heart, and arterial 
wall 67.   
Transforming growth factor β1, β2 and β3 play a pivotal role in the regulation of 
lung fibrosis. Transforming growth factor β modulates lung fibrosis through recruitment 
and activation of monocytes and fibroblasts, induction of ECM, and stimulation of 
smad2/3
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angiogenesis. Fibroblasts are induced by TGF-β to differentiate into myofibroblasts, 
which represents the main source of ECM during pulmonary fibrosis. Transforming 
growth factor β signalling modulates ECM production by promoting ECM gene 
transcription, including collagens I, III, IV, and V, fibronectin, and proteoglycans, and by 
suppressing the activity of MMPs, plasminogen activators, and elastases, which results in 
the inhibition of collagen degradation 68-72. Moreover, the intracellular factor Smad3 has 
been demonstrated to be downstream of TGF-β1 in studies on the targeted repression of 
this pathway in mice, which fail to develop pulmonary fibrosis when challenged with TGF-
β1 73-75. Additionally, TGF-β1 levels are elevated in fibrotic organs, and are often 
specifically localised to fibrotic areas. This is correlated with increased level of Smad2, 
Smad3 and Smad4, but reduced level of Smad7, which was investigated in cardiac 
fibrosis 76. 
The potent profibrotic cytokine TGF-β induces matrix synthesis in fibroblasts and 
fibrotic responses in vivo and in vitro. Genetic and pharmacological studies have 
suggested the broad targeting of general TGF-β signalling pathways might be optional for 
treating fibrotic diseases, but on the other hand could be problematic due to the 
pleiotropic nature of TGF-β. However, further clarification of the differential contribution of 
TGF-β to the pathogenesis of IPF may lead to the discovery of novel therapeutic options 
for the treatment of fibrotic diseases. 
 
 
 
 
1.3. Two distinct TGF-β type I receptors: ALK1 and 
ALK5 
The actions of TGF-β are highly dependent on cellular context. In TGF-β 
signalling, one TGF-β type II receptor and two distinct TGF-β type I receptors, the 
endothelium restricted activin receptor-like kinase (ALK)1 and the broadly expressed 
ALK5, have been implicated. Recent studies now challenge the previous dogma 
concerning receptor complexes and signal transduction schemes and demonstrate that, 
in endothelial cells (ECs), TGF-β signals through a heteromeric receptor complex 
consisting of TGF-βRII, ALK5 and ALK1, resulting in activation of both classes of Smad 
proteins, which mediate both selective and antagonistic effects on the transcriptional 
output.  
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1.3.1. The ALK1/ALK5 balance in endothelial cells 
In the vascular system, TGF-β regulates the process of angiogenesis, which 
involves the activation, remodelling, and expansion of pre-existing networks of vessels. 
Vessels are formed by two main cell types – ECs and perimural cells – that enshroud the 
endothelium. Angiogenesis can be divided into an activation phase and a resolution 
phase. Under baseline conditions, the endothelium is quiescent due to the stabilisation of 
the vessels by mural cells. During the activation phase, smooth muscle cells detach, 
vascular basement membranes depredate, and EC proliferate and migrate, to form a new 
tube. During the resolution phase, basement membrane is reformatted, smooth muscle 
cells are recruited to cover the new tube and to inhibit the proliferation and migration of 
the endothelial cells 77. These two phases are self-limiting processes in the human body. 
The existence of a balance between activation and resolution phase of angiogenesis is 
pivotal for homeostasis. 
One of the aspects that have puzzled researchers for years is that TGF-β exerts 
bifunctional effects on EC proliferation: TGF- can both stimulate and inhibit proliferation 
of ECs. Low doses of TGF-β stimulate EC proliferation and migration, while high doses of 
TGF-β inhibit these processes 78. Recent results have reported that TGF-β regulates the 
activation state of the endothelium via a fine balance between ALK5 and ALK1 signalling 
(Figure 1.6.) 79. 
Although ALK5 is a predominant receptor that mediates TGF-β signalling, ALK1 
can also form complexes with the type II receptor. In ECs, both ALK1 and ALK5 are 
expressed and bind TGF-β. Activin receptor-like kinase 1 expression is restricted to the 
ECs and during embryogenesis at active sites of angiogenesis.  
Transforming growth factor β/activin receptor-like kinase 5 signalling induces 
Smad2/3 phosphorylation and blocks angiogenesis by inhibiting EC proliferation, tube 
formation and migration 79, 80. Activin receptor-like kinase 5 induces the expression of 
fibronectin and plasminogen activator inhibitor type 1 (PAI1), a negative regulator of EC 
migration. Activin receptor-like kinase 5 has been reported to increase TGF-β-induced 
EC permeability and actin cytoskeleton remodelling 81. By enhancing TGF-βRII/ALK5 
assembly, clustered VE-cadherin promotes persistent and elevated TGF-β-induced 
Smad2/3 activation, indicating a positive role for VE-cadherin in TGF-β/ALK5-induced 
vessel stabilisation 82. Taken together, TGF-β/ALK5 signalling plays an important role in 
keeping the endothelium quiescent. 
In contrast to TGF-β/ALK5, TGF-β/ALK1 signalling induces Smad1/5 activation 
and has been shown to stimulate EC migration, proliferation and tube formation 80. 
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Caveolin1 was shown to associate with ALK1 and to promote TGF-β/ALK1-induced 
responses 83. An important intracellular effector of ALK1 is inhibitor of differentiation 1, an 
inhibitor of basic helix-loop-helix proteins that promotes angiogenesis. Its upregulation 
was shown to be required for TGF-β/ALK1-induced EC migration and tube formation 79. 
However, an inhibitory effect of ALK1 signalling on EC proliferation, migration and 
sprouting has also been reported 84-87. Bone morphogenetic protein 9, identified as a 
ligand for ALK1 and BMPRII complex in ECs, was shown to inhibit EC migration and 
VEGF-induced angiogenesis 88, 89. These observations suggest that the effect of ALK1 
signalling on angiogenesis is dependent on the context and specific ligand by which it is 
activated 90. 
 
 
 
Figure 1.6. A model of TGF-β control of the angiogenic switch.  
Transforming growth factor β regulates the state of the endothelium via a balance between ALK1 
and ALK5 signalling. Activation of ALK5, phosphorylates Smad2/3, which induces PAI1 and 
fibronectin expression and inhibits migration, proliferation, and tube formation, resulting in the 
resolution phase of angiogenesis. Transforming growth factor β binding to ALK1 leads to the 
phosphorylation of Smad1/5, which induces Id1 expression and stimulates migration and 
proliferation, processes involved in the activation phase of angiogenesis 
91
.  
 
 
Activin receptor-like kinase 1 and ALK5 signalling not only elicit opposite 
responses, but also physically interact with each other in ECs. Activin receptor-like kinase 
5-deficient ECs are not only defective in TGF-β/ALK5 signalling but also exhibit impaired 
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TGF-β/ALK1 responses; ALK5 was found to be necessary for recruitment of ALK1 into a 
TGF-β receptor complex, and the kinase activity of ALK5 is essential for maximal ALK1 
activation 80. Furthermore, ALK1 can directly antagonise ALK5/Smad2/3 signalling at the 
level of Smads 86. The cross-talk between ALK1 and ALK5 signalling provides ECs with a 
TGF-β-dependent switch to fine-tune EC function.  
 Interestingly, there are endothelial cells that express betaglycan and those that 
express endoglin. Endothelial cells expressing betaglycan respond to all three isoformes 
of TGF-β, whereas ECs that express endoglin respond to TGF-β1 and –β3, but not –β2 
92. The co-receptor endoglin is predominantly expressed in highly proliferating vascular 
ECs. Endoglin regulates the fine-tuning between the ALK1 and ALK5 signalling 
pathways. Endoglin is required for TGF-β/ALK1 signalling and indirectly inhibits TGF-
β/ALK5 signalling 93, 94, thus promoting the activation phase of angiogenesis. Moreover, in 
the absence of endoglin, ECs do not grow and ALK1 signalling is abrogated whereas 
ALK5 signalling is stimulated. Endoglin may thus function as a modulator of the balance 
between the TGF-β/ALK1 and the TGF-β/ALK5 signalling pathways 95. 
 
 
1.3.2. Fibrosis and angiogenesis 
In recent years, several new discoveries have been made in the fields of fibrosis 
and angiogenesis 47, 67, 96, 97. Although most of these discoveries were made in the context 
of either fibrosis or angiogenesis, a new appreciation for a connection between these two 
fields is emerging. The cytokines and ECM molecules involved in fibrosis are also pivotal 
for the formation of new capillaries 98.  
Extracellular matrix proteins exist outside the cells to provide structural and 
functional support for cells. Extracellular matrix also exists as thin layer called the 
basement membrane, which provides a supporting structure on which epithelial and 
endothelial cells can grow. Vascular basement membrane (VBM) constitutes the rigid 
structural wall of newly-established capillaries, and is speculated to play an important role 
in regulating pro- and anti-angiogenic events. In this regard, several endogenous 
inhibitors of angiogenesis have been discovered, which are fragments of ECM molecules. 
These fragments of large collagen proteins, are released by the action of matrix-
degrading enzymes such as MMPs and elastase during the activation phase of 
angiogenesis, and during the resolution phase the expression of these proteases is 
downregulated, and the expression of matrix proteins is upregulated in association with 
the formation of new VBM, pericyte proliferation and attachment 99. In future, it will be 
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interesting to study the role of these inhibitors of angiogenesis in organ fibrosis and organ 
development. Similarly, during fibrosis, the expression of these enzymes is significantly 
downregulated and the expression of inhibitors of these enzymes, such as TIMPs, is 
upregulated. These observations suggest that fibrosis and angiogenesis share some 
common features. One example of he coordinated interplay of molecular mechanisms 
associated with fibrosis and angiogenesis is the process of wound healing 98. 
Transforming growth factor β is produced by many different cell types, including 
epithelial cells, endothelial cells and cells of mesenchymal origin, and is typically a 
negative regulator of cell proliferation in epithelial and endothelial cells but a positive 
regulator in mesenchymal cells 49, 59. Many different cell types including fibroblasts, 
endothelial and epithelial cells respond to TGF-β by upregulating the expression of matrix 
and matrix-associated proteins such as fibronectin, collagens, proteoglycans, laminin and 
thrombospondin. Transforming growth factor β is associated with the increasing level of 
PAI1, TIMPs and integrins, and with decreasing level of MMPs and plasminogen 
activators 70, 99. Interestingly, in the context of fibrosis and angiogenesis all these 
molecules exhibit the same pattern of expression 100.  
TGF-β can induce the formation of new blood vessels in vivo, essentially in 
concert with basic fibroblast growth factor (bFGF) 100, 101. Transforming growth factor β 
may have growth inhibitory effects on endothelial monolayer, and play a role in pericyte 
maturation, indicating a role for this cytokine in the resolution phase of angiogenesis. 
Additionally, as described in the chapter 1.2.5., TGF-β plays a pivotal role in the 
pathogenesis of idiopathic pulmonary fibrosis. The question remains, however, as to 
whether the two processes are mediated by the same or different activities of TGF-β, or 
by specific switch between the TGF-β receptors and intracellular mediators. 
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2. Aim of the study 
It is well established that an imbalance between ALK1/ALK5 may contribute to the 
development of several diseases, including HHT, pulmonary hypertension and fibrosis. 
These TGF-β type I receptors may significantly affect collagen synthesis due to their 
opposite effect on the different cell proliferation, migration and differentiation, and the 
subsequent collagen deposition. As these processes are reported to be involved in the 
pathogenesis of the fibrosis of many organs, this project aims to functionally characterise 
the action of ALK1 in idiopathic pulmonary fibrosis. In this context, the research focus 
was: 
 
1. The expression analysis of ALK1/ALK5 receptors in the human lungs exhibiting 
the pathological features of IPF and the human lung fibroblasts 
2. The elucidation of the role of ALK1 receptor and its impact on fibroblasts 
activation and collagen deposition. 
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3. Materials and Methods 
3.1. Materials 
3.1.1. Equipment 
ABI PRISM 7500 Sequence Detection System  Applied Biosystems, USA 
Cell Culture Incubator; Cytoperm2     Heraeus, Germany 
Developing machine; X Omat 2000     Kodak, USA 
Electrophoresis chambers      Bio-Rad, USA 
Film cassette       Sigma-Aldrich, Germany 
Filter Tip FT: 10, 20, 100, 200, 1000    Greiner Bio-One, Germany 
Filter units 0.22 μm syringe-driven     Millipore, USA 
Freezer -20 °C      Bosch, Germany 
Freezer -40 °C      Kryotec, Germany 
Freezer -80 °C      Heraeus, Germany 
Fridge +4 °C       Bosch, Germany 
Fusion A153601 Reader      Packard Bioscience, 
Germany  
Gel blotting paper 70 × 100 mm     Bioscience, Germany 
Glass bottles: 250, 500, 1000 ml     Fischer, Germany 
GS-800TM Calibrated Densitometer    Bio-Rad, USA 
Light microscope Olympus BX51     Olympus, Germany 
Mini spin centrifuge       Eppendorf, Germany 
Multifuge centrifuge, 3 s-R      Heraeus, Germany 
Multipette® plus      Eppendorf, Germany 
Nanodrop®       Peqlab, Germany 
PCR-thermocycler       MJ Research, USA 
Pipetboy        Eppendorf, Germany 
Pipetman: P10, P20, P100, P200, P1000    Gilson, France 
Power Supply; Power PAC 300     Bio-Rad, USA 
Petri dish         Greiner Bio-One, Germany 
Pipette tip: 200, 1000 μl,     Sarstedt, Germany 
Pipette tip: 10 μl, 20 μl, 100 μl    Gilson, USA 
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Radiographic film X-Omat LS     Sigma-Aldrich, Germany 
Serological pipette: 5, 10, 25, 50 ml    Falcon, USA 
Test tubes: 15, 50 ml      Greiner Bio-One, Germany 
Thermo-Fast® 96 PCR Plate     Thermo Scientific, USA 
Tissue culture dish 100 mm      Greiner Bio-One, Germany 
Tissue culture flask 250 ml      Greiner Bio-One, Germany 
Tissue culture plates: 6, 48 well    Greiner Bio-One, Germany 
Western Blot Chambers: Mini Trans-Blot    Bio-Rad, USA 
Vortex machine       Eppendorf, Germany 
Vacuum centrifuge      Eppendorf, Germany 
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3.1.2. Reagents 
Acetone pure       Merck, Germany 
Acrylamide solution, Rotiphorese Gel 30   Roth, Germany 
Agarose        Invitrogen, UK 
Albumine, bovine serum     Sigma-Aldrich, Germany 
Ammonium persulfate     Promega, Germany 
β-glycerophosphate      Sigma-Aldrich, Germany 
β-mercaptoethanol       Sigma-Aldrich, Germany 
Bone morphogenetic protein 2 (BMP2)   R&D Systems, USA 
Bromophenol blue       Sigma-Aldrich, Germany 
CompleteTM Protease inhibitor    Roche, Germany 
D-(+)-Glucose       Sigma-Aldrich, Germany 
D-MEM + GlutaMAXTM -I (1×) medium    Gibco BRL, Germany 
D-MEM/F12 + GlutaMAXTM -I (1×) medium   Gibco BRL, Germany 
D-MEM medium      Sigma-Aldrich, Germany 
Dimethyl sulfoxide      Sigma-Aldrich, Germany 
DNA Ladder (100 bp, 1 kb)     Promega, USA 
Ethylendinitrilo-N, N, N´, N´, -tetra-acetic-acid  
(EDTA)        Promega, USA 
Ethylene glycol-bis (2-amino-ethylether)-N,N, N´, N´ 
-tetraacetic-acid (EGTA)     Sigma-Aldrich, Germany 
Dulbecco’s phosphate buffered saline 10× PAA Laboratories, Austria 
Dulbecco’s phosphate buffered saline 1× PAA Laboratories, Austria 
Ethanol absolute       Riedel-de Haën, Germany 
ECL Plus Western Blotting Detection System  Amersham Biosciences, UK 
Ethidium bromide      Roth, Germany 
Foetal calf serum (FCS)     PAA Laboratories, Austria 
Glycine       Roth, Germany 
GoTaq® Flexi DNA polymerase    Promega, USA 
Hydrochloric acid       Sigma-Aldrich, Germany 
2-(4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate  
(HEPES)       Sigma-Aldrich, Germany 
Igepal CA-630       Sigma-Aldrich, Germany 
MuLV Reverse Transcriptase    Applied Biosystems, USA 
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L-Glutamine 200 mM (100×)     PAA Laboratories, Austria 
LipofectamineTM 2000     Invitrogene, UK 
Luciferase Assay Reagent 10-Pack    Promega, USA 
Luciferase Cell Culture Lysis 5× Reagent   Promega, USA 
Magnesium chloride       Sigma-Aldrich, Germany 
Methanol        Fluka, Germany 
N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) Bio-Rad, USA 
Non-essential amino acids      PAA Laboratories, Austria 
Opti-MEM medium       Gibco BRL, Germany 
PCR Nucleotide Mix      Promega, USA 
Penicillin-streptomycin     PAA Laboratories, Austria 
Potassium acetate       Sigma-Aldrich, Germany 
Potassium borate  Grom-chromatography, 
Germany 
Potassium chloride       Merck, Germany 
Potassium phosphate      Sigma-Aldrich, Germany 
Precision Plus ProteinTM Standards     Bio-Rad, USA 
2-Propanol        Merck, Germany 
Pure Yield Plasmid Midiprep System   Promega, Germany 
QIAprep Spin Miniprep Kit     Qiagen, Germany 
Quick StartTM Bradford Dye Reagent   Bio-Rad, USA 
Random Hexamers (50 μM)     Applied Biosystems, USA 
RNase inhibitor      Applied Biosystems, USA 
RNaseZAP®       Sigma-Aldrich, Germany 
PeqGOLD Total RNA Kit     Peqlab, Germany 
Roti®-Quick-Kit       Roth, Germany 
Silencer® Negative siRNA control #1 (50 μM)  Ambion, Germany 
SircolTM, Soluble Collagen Assay    Biocolor, UK 
Sodium acetate       Sigma-Aldrich, Germany 
Sodium chloride       Merck, Germany 
Sodium dodecyl sulfate (SDS)    Promega, USA 
Sodium ortho vanadate     Sigma-Aldrich, Germany 
Sodium phosphate       Sigma-Aldrich, Germany 
SuperSignal® West Pico Chemiluminescent  
Substrate       Thermo Scientific, USA 
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SYBER® Green PCR Kit     Invitrogene, UK 
Transforming growth factor β1 (TGF-β1)   R&D Systems, USA 
Tween 20        Sigma-Aldrich, Germany 
Tris         Roth, Germany 
Triton X-100        Promega, USA 
Trypsin-EDTA       Gibco BRL, Germany 
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3.1.3. Mammalian cells 
3.1.3.1. Cell lines 
HFL1 (human foetal lung fibroblasts), ATCC, USA 
IMR-90 (human lung fibroblasts), ATCC, USA 
 
 
3.1.3.2. Primary cells  
Human primary lung fibroblasts were isolated from tissues obtained from healthy 
transplant donors and fibrotic patients, as described in section 3.2.11.2.  
 
 
3.1.4. Human tissues 
Lung tissue samples were obtained from twelve patients with IPF (mean age 51 ± 
11 years) and twelve control subjects (mean age 48 ± 14 years). The study protocol was 
approved by the Ethics Committee of the University of Giessen School of Medicine (AZ 
31/93). Informed consent was obtained from each subject for the study protocol.  
 
 
 
 
3.2. Methods 
3.2.1. RNA isolation 
Isolation of RNA from lung tissue and cultured cells material was performed 
according to the manufacturer’s instructions provided with Roti®-Quick-Kit and peqGOLD 
Total RNA Kit, respectively. 
 
 
3.2.2. Determining RNA concentration 
The concentration of isolated RNA was determined according to a protocol from 
Peqlab by applying 1.5 l of the sample to a Nanodrop®  spectrophotometer. 
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3.2.3. Reverse transcription reaction 
Reverse transcription polymerase chain reaction (RT-PCR) is an enzymatic 
process performed by an enzyme called reverse transcriptase. This enzyme synthesises 
complementary DNA (cDNA) using RNA as a template.  
In order to perform RT-PCR, 500 ng of human total RNA was added to the 
autoclaved water up to 10 μl of total volume. The reaction mixture was heated to 70 °C 
for 15 min, chilled on ice, and the following RT reagents were added: 
 
RT reaction component Volume Final concentration 
10× RT Buffer II (MgCl2  
free) 
2 μl 1× 
25 mM MgCl2 4 μl 5 mM 
10 mM dNTP mix 1 μl 0.5 mM 
Random hexamers (50 μM) 1.5 μl 3.75 μM 
RNAse inhibitor (20 U/μl) 0.5 μl 10 U 
Reverse transcriptase  
(50 U/μl) 
1 μl 50 U 
 
To synthesise cDNA, the reaction mixture was incubated at 20 °C for 10 min, then 
at 43 °C for 75 min and at 99 °C for 5 min. Synthesised cDNA was stored either at -20 °C 
or used for other experiments immediately. 
 
 
3.2.4. Polymerase chain reaction 
The polymerase chain reaction (PCR) is an enzymatic technique that facilitates 
the production of millions of copies of specific DNA. An enzyme called DNA polymerase 
carries out the amplification of cDNA, previously reverse-transcribed from RNA. 
Principally, each PCR cycle consists of three steps: 
 
Denaturation - separation of double-stranded DNA into single strands, 
Annealing  - primer binding to the appropriate sequence of single DNA 
strands, 
Elongation - synthesis of a new DNA strand by DNA polymerase. 
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3.2.4.1. Semi-quantitative polymerase chain reaction  
A semi-quantitative PCR reaction proceeds, in principal, as described in section 
3.2.3. Amplification of cDNA was performed according to the manufacturer’s instructions 
provided with the GoTaq® Flexi DNA Polymerase. The PCR reaction mix was prepared 
as follows: 
 
PCR reaction component Volume Final concentration 
5× PCR Buffer (free MgCl2) 10 μl 1× 
25 mM MgCl2 5  μl 2.5 mM 
10 mM dNTP mix 1 μl 0.2 mM 
10 μM forward primer* 1 μl 0.2 μM 
10 μM reverse primer* 1 μl 0.2 μM 
Taq DNA Polymerase (5 U/μl) 0.25 μl 1.25 U 
cDNA template 1 μl not applicable 
H2O (autoclaved) up to 50 μl not applicable 
 
* All primer sequences are listed in Table 6.1.2. 
 
The PCR reaction components were mixed on ice and transferred to a PCR 
machine. To perform effective amplification of cDNA, the following program was 
performed: 
 
Step Time Temperature 
First denaturation 5 min 95 °C 
Second denaturation 1 min 95 °C 
Annealing 0.5-1 min 57-60 °C* 
Elongation 1 min 72 °C 
Final extension  10 min 72 °C 
 
* Annealing temperatures varied depending on the primers used in the experiment. 
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The steps were repeated for 22-28 cycles depending on the amplified sequence. 
Amplicons were immediately separated by the agarose gel electrophoresis and visualised 
by staining with ethidium bromide. 
 
 
3.2.4.2. Real-time polymerase chain reaction 
Quantitative real-time PCR is used to simultaneously quantify and amplify specific 
sequence of DNA. The procedure follows the PCR strategy but after each amplification 
round, the DNA is quantified. Quantification is performed by means of fluorescent dye – 
SYBR® Green I – that directly binds to double-stranded DNA. The bound dye generates a 
signal that is proportional to the DNA concentration.  
Reactions were performed according to the manufacturer’s instructions provided 
with a SYBER® Green PCR Kit. PCR reaction mix was prepared as follows: 
 
PCR reaction component Volume Final concentration 
Platinum
®
 Syber
®
 Green 
qPCR SuperMix-UDG 
13 μl 1× 
50 mM MgCl2 1  μl 2 mM 
10 μM forward primer* 0.5 μl 0.2 μM 
10 μM reverse primer* 0.5 μl 0.2 μM 
cDNA template 2 μl not applicable 
H2O (autoclaved) up to 25 μl not applicable 
 
* All primer sequences are listed in Table 6.1.1. 
 
The amplification and quantification of cDNA was carried out by means of 
following program: 
 
Step Time Temperature 
Activation of polymerase enzyme 2 min 50 °C 
First denaturation 5 min 95 °C 
Second denaturation 5 s 95 °C 
Annealing 5 s 59-60 °C* 
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Elongation 30 s 72 °C 
Dissociation step 1 15 s 95 °C 
Dissociation step 2 1 min 60 °C 
Dissociation step 3 15 s 95 °C 
Dissociation step 4 15 s 60 °C 
 
*Annealing temperatures varied depending on the primers used in the experiment. 
 
The steps were repeated for 45 cycles. 
A ubiquitously and equally-expressed gene that is free of pseudogenes was used 
as the reference gene in all quantitative real-time PCR reactions. The relative transcript 
abundance of a gene was presented as ∆Ct values (∆Ct = Ct reference – Ct target). Relative 
changes in transcript levels compared to controls were displayed as ∆∆Ct values (∆∆Ct = 
∆Ct treated – ∆Ct control). All ∆∆Ct values corresponded approximately to the binary logarithm 
of the fold change. 
 
 
3.2.5. DNA agarose gel electrophoresis 
Agarose gel electrophoresis was performed in order to separate and analyse DNA 
products obtained by PCR. Percentage of the gels varied 1–2.5 % depending on the size 
of the DNA amplicon. Agarose was mixed with 1× Tris-acetate-EDTA (TAE) buffer and 
0.5 μg/ml ethidium bormide, a DNA intercalating dye, that enables visualisation of the 
DNA fragments under ultraviolet light. The DNA samples were mixed with 6× DNA 
loading buffer and loaded onto the gel. Electrophoresis was performed at 100 V/cm in 1× 
TAE buffer. 
 
1× TAE:  
40 mM Tris-acetate, pH = 8.0 
1 mM EDTA, pH = 8.0 
 
6× DNA loading buffer: 
0.025 % (w/v) bromophenol blue 
40 % (w/v) sucrose 
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3.2.6. Protein isolation 
Proteins were extracted from either total lung tissue or mammalian cells. 
Depending on the biological material, two different extraction procedures were 
performed. 
 
 
3.2.6.1. Protein isolation from tissues 
Lung tissue preserved in liquid nitrogen was homogenised by addition of ice-cold 
tissue lysis buffer. Tissue lysate was then passed 5–8 times through a 0.9 mm gauge 
needle fitted to an RNAse-free syringe. Homogenised tissue was then incubated for      
30 min on ice and centrifuged 15000 × g for 15 min at 4 °C. Resulting supernatant was 
used as tissue extracts and stored at -20 °C for further experiments.  
 
Tissue lysis buffer: 
20 mM Tris-HCl, pH = 7.5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1 % Trition X-100 
2.5 mM Na3PO4 phosphatase inhibitor 
1 mM -glycerophosphate inhibitor 
1 mM Na3VO4, phosphatese inhibitor – added immediately prior to 
homogenisation 
Complete™, protease inhibitor mix – added immediately prior to homogenisation 
 
 
3.2.6.2. Protein isolation from cells 
Cells were harvested at indicated time points by scraping in the cell lysis buffer 
with a rubber policeman. Collected cells were passed 5–8 times through a 0.9 mm gauge 
needle until a homogenous lysate was obtained. Lysates were then incubated for 30 min 
on ice and centrifuged 15000 × g for 15 min at 4 °C. Resulting supernatants were used 
as cell extracts and stored at -20 °C for further experiments.  
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Cell lysis buffer: 
20 mM Tris-HCl, pH = 7.5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
0.5 % Igepal CA-630 
1 mM Na3VO4, phosphatese inhibitor – added immediately prior to 
homogenisation 
Complete™, protease inhibitor mix – added immediately prior to homogenisation 
 
 
3.2.6.3. Protein precipitation from cell culture media 
Three ml of cell culture media was collected in 15-ml Falcon tubes after the 
experiments were performed. Twelve ml of acetone was added and the mixture was 
incubated for over night at -20 °C. The following day, the samples were centrifuged 
13000 × g for 20 min at 4 °C. The acetone was removed completely by evaporation at 
room temperature. Collected pellets were resuspended in cell lysis buffer (the same used 
for protein isolation from cells) and passed 5–8 times through a 0.9 mm gauge needle 
until a homogenous lysate was obtained. Lysates were then incubated for 30 min on ice 
and centrifuged 15000 × g for 15 min at 4 °C. The resulting supernatants were stored at   
-20 °C for further experiments. 
 
 
3.2.6.4. Protein quantification 
Protein concentrations in tissue and cell extracts were spectrophotometrically 
determined using Quick Start™ Bradford Dye Reagent and a Fusion A153601 Reader 
according to the manufacturer’s instructions. The protein assay is based on the colour 
change of Coomassie Brilliant Blue G-250 dye after binding proteins. The dye binds 
primarily to basic and aromatic amino acids residues. The 10 μl of sample was mixed 
with 200 μl of Bradford Dye Reagent and transferred to a 96-well plate. Six dilutions of 
protein standard, bovine serum albumin, 0.05–0.5 μg/μl, were prepared and mixed with 
Bradford Dye Reagent in the same ratio as the sample of unknown concentration. 
Reaction mixtures were incubated for 15 min at room temperature. The absorbance of 
the samples was measured at 570 nm. The unknown amount of protein in the sample 
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was determined by interpolation, reading the concentration of protein on the standard 
curve that corresponded to its absorbance. 
 
 
3.2.7. SDS polyarcrylamide gel electrophoresis 
Protein extracts were separated by means of SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). Before loading onto the gel, 30 μg of protein was combined 
with 10 × SDS-loading buffer and denaturated by heating for 10 min at 95 °C. Separation 
of proteins was performed in the gel consisting of 5 % stacking gel and 10 % resolving 
gel. Electrophoresis was carried out in SDS-running buffer at 120 V.  
 
10× SDS-loading buffer: 
625 mM Tris-HCl, pH = 6.8 
50 % (v/v) glycerol 
20 % (w/v) SDS 
9 % (v/v) -mercaptoethanol 
0.3 % (w/v) bromophenol blue 
 
Stacking gel:  
5 % acrylamide:bisacrylamide 
125 mM Tris-HCl, pH = 6.8 
0.1 % (w/v) SDS 
0.1 % (w/v) APS 
0.1 % (v/v) TEMED 
 
Resolving gel: 
10 % acrylamide:bisacrylamide 
375 mM Tris-HCl, pH = 8.8 
0.1 % (w/v) SDS 
0.1 % (w/v) APS 
0.1 % (v/v) TEMED 
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SDS-running buffer: 
25 mM Tris  
250 mM glycine 
0.1 % (w/v) SDS 
 
 
3.2.8. Immunoblotting 
Immunoblotting was performed in order to visualise and detect specific proteins 
separated by SDS-PAGE.  
 
 
3.2.8.1. Protein blotting 
Proteins separated by SDS-PAGE were transferred to 0.25 μm pure nitrocellulose 
membrane. Transfer was performed in transfer buffer at 120 V for 1 h.  
 
Transfer buffer: 
25 mM Tris 
192 mM glycine 
20 % (v/v) methanol  
 
 
3.2.8.2. Protein detection 
Membranes were blocked in blocking solution for 1 h at room temperature. After 
blocking, membranes were incubated with the appropriate primary antibodies for 
overnight at 4 °C *. Membranes were washed three times for 10 min with 1× Phosphate-
buffered saline + 0.1 % Tween 20 (PBST) buffer, incubated with horseradish peroxidase-
labeled secondary antibody for 1 h at room temperature, and then washed five times for 
10 min with 1× PBST. Specific bands were visualised by chemiluminescence using an 
Enhanced Chemiluminescence Immunoblotting system. In order to re-probe membranes 
with another antibody, membranes were stripped with stripping buffer for 15 min at 52  C 
and subsequent protein detection was performed as described above.  
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Blocking solution: 
5 % (w/v) non-fat dry milk 
1× PBS 
0.1 % (v/v) Tween-20 
 
1× PBST: 
1× PBS 
0.1 % (v/v) Tween-20 
 
Stripping buffer: 
62.5 mM Tris-HCl, pH = 6.8 
2 % (w/v) SDS 
100 mM -mercaptoethanol  
 
* Primary antibody concentrations varied depending on the antibodies used in the 
experiment, and are presented in Tables 6.2.1. and 6.2.2. 
 
 
3.2.9. Immunohistochemistry 
In order to localise and detect the expression of proteins in lung tissue, 
immunochistochemical analysis was performed using a Histostain-SP Kit. Whole lung 
sections were deparaffinised in xylene, three times for 10 min, and rehydrated in 100 % 
ethanol twice for 5 min, 95 % ethanol twice for 5 min, 70 % ethanol twice for 5 min, and 
1× PBS twice for 5 min. Antigen retrieval was performed by incubation of the slides in 1× 
citrate buffer for 20 min at 100 °C, followed by cooling the slides for 10 min. Endogenous 
peroxidase activity was quenched by incubating sections with 3 % (v/v) H2O2 for 10 min. 
Sections were blocked with blocking solution provided in the kit for 10 min at room 
temperature, followed by incubation with the primary antibody overnight at 4 °C *. Normal 
mouse IgG was used as a negative control. Sections were washed twice with 1× PBS for 
5 min, and incubated with biotinylated secondary antibodies for 10 min, followed by the 
Streptavidin-conjugated enzyme for 10 min, and chromogenic substrate for 10 min. 
Slides were developed for 5 min with diaminobenzidine (DAB) and counterstained with 
Mayers hematoxylin. Sections were mounted using mounting medium and examined for 
staining using an Olympus BX51 microscope. 
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* Primary antibody concentrations varied depending on the antibodies used in the 
experiment, and are presented in Tables 6.2.1. and 6.2.2. 
 
 
3.2.10. Culture of mammalian cells 
3.2.10.1. Cell culture condition 
The human fibroblast cell lines, HFL1 and IMR-90, and primary human lung 
fibroblasts were grown in plate culture dishes in appropriate medium containing 10 % 
(v/v) foetal calf serum (FCS) at 37 °C, 5 % CO2 and 95–100 % humidity. Human foetal 
lung fibroblasts 1 were grown in D-MEM/F12 + GlutaMAXTM -I (1×), IMR-90 in D-MEM + 
GlutaMAXTM -I (1×) containing additionally non-essential amino acids and primary human 
lung fibroblast in D-MEM containing additionally 10.4 mM HEPES and 4 mM (1×)           
L-glutamine. Cells were passaged after achieving 80-90 % confluence. Cells were 
washed with 1× PBS and then incubated with 3 ml trypsin/EDTA solution for 2–3 min in 
order to detach the cells. The 7 ml of D-MEM containing FCS was added to cells to 
further block the enzymatic reaction. The cell suspension was transferred to the new 
culture dishes in dilution 1:5 or 1:10.  
 
PBS (phosphate-buffered saline): 
0.08 % (w/v) NaCl 
0.02 % (w/v) KCl 
0.115 % (w/v) Na2HPO4 2H2O 
0.02 % (w/v) KH2PO4 2H2O 
pH = 7.4 adjusted with NaOH; sterilised for 20 min at 121 °C, 15 psi 
 
Trypsin/EDTA solution: 
0.25 % (w/v) trypsin 
1.23 g/l EDTA 
 
 
3.2.10.2. Isolation of primary lung fibroblasts 
Human lung primary fibroblasts were derived from healthy transplant donors and 
patients with IPF. In order to isolate primary lung fibroblasts, lungs were perfused free of 
Materials and Methods  36 
 
blood, and individual lung lobes were removed to a petridish. Using sterile technique, 
lung lobes were finely minced with scissors, and the minced lungs were cultured for     
10–14 days in D-MEM containing 10 % FCS, 10.4 mM HEPES, 4 mM (1×) L-glutamine 
and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin). After 10 days, fibroblasts 
had grown out from the tissue and were passaged by standard trypsinisation. To insure 
the purity of the culture, cells were morphologically characterised by light microscopy, 
additionally specific staining for α-SMA was performed. For experiments described here, 
the cells were used between the second and fifth subpassages. Cells were plated at 
30000 cells/cm2 either in 6-well plates or in 100-mm plates, depending on the experiment. 
 
 
3.2.10.3. Transfection with small interfering RNA 
The ON-TARGETplus SMARTpool siRNA oligonucleotides specific for human 
ALK1 and ALK5 mRNA (Table 6.3.) were obtained from Dharmacon Inc. (Lafayette, 
USA). Human foetal lung fibroblasts 1 cells were transiently transfected with 100 nM 
ALK1 or ALK5 siRNA or Silencer® Negative siRNA control #1 using DharmaFECT 1 
transfection reagent. Briefly, DharmaFECT 1 was added to OptiMEM and incubated for   
5 min. Short interference ALK1, siALK5 or non-specific siRNA was added to OptiMEM, 
and this mix was transferred into DharmaFECT 1 and OptiMEM mix after 5 min. The mix 
was incubated for another 20 min at room temperature with constant shaking. Afterwards 
the siRNA mix was added to the cells, after 24 h cells were lysed, and efficiency of gene 
knockdown was monitored by real-time PCR. 
 
 
3.2.10.4. Calculations for siRNA data 
The remaining gene expression calculated as a percent and percent knockdown 
of gene expression was determined to asses the effect of siRNA on the silencing the 
target gene with real-time PCR. The CT method (ΔΔCT) for relative quantitation is a 
commonly used method for measuring siRNA-induced knockdown of a particular gene. In 
this method, data are normalised using a control transcript (PBGD), and the normalised 
expression value (ΔCT) for the gene of interest in the experimental sample is compared to 
the equivalent ΔCT  for the negative control siRNA-treated sample by calculating ΔΔCT 
(ΔCT-Sample - ΔCT-Negative control ). The ΔΔCT is used to calculate then the percent remaining 
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gene expression (% Remaining = 2-ΔΔCT ) and the percent knockdown (% Knockdown = 
100-% Remaining) 102 . 
 
 
3.2.11. Sircol collagen assay 
Total collagen content in cell lysates was determined using the Sircol Collagen 
Assay Kit according to the manufacturer’s instructions. This is a quantitative dye–binding 
method designed to analyse the amount of collagen produced in mammalian tissues or 
cells during in vitro culture. The dye reagent contains the Sirius Red anion with sulfonic 
acid side chain groups, which reacts with the side chain groups of the basic amino acids 
present in collagen.  
Equal amounts of cell lysates containing 100 μg of protein were added to 1 ml of 
Sircol dye reagent followed by 30 min of mixing at room temperature. After centrifugation 
at 10000 × g for 10 min, the supernatant was carefully removed and 1 ml of alkali reagent 
was added, and the pellet was dissolved by vortexing. Samples and collagen standards 
were analysed at 540 nm in a Fusion A153601 Reader. Collagen concentrations were 
calculated using standard curve with acid–soluble type I collagen. 
 
 
3.2.12.  Statistical analysis of data 
 Values are presented as mean ± SEM. The mean of indicated groups were 
compared using two-tailed Student´s t-test. A level of p<0.01, p<0.02, p<0.05, p<0.005, 
or p<0.0005 was considered statistically significant, depending on the experiment. All 
experiments were performed at least three times.  
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4. Results 
4.1. Analysis of the expression of TGF-β system 
components in human lungs 
4.1.1. Expression analysis of TGF-β receptors by semi-
quantitative PCR 
  To investigate potential changes in the levels of the TGF-β system components in 
human lungs, mRNA expression of TGF-β receptors in human lung tissue was analysed. 
The RNA was isolated from human lung homogenates of transplant donors and IPF 
patients. The mRNA levels of receptors were determined by semi-quantitative RT-PCR 
(Figure 4.1.). No significant changes in the expression were observed in most of the 
receptors. Interestingly, only TGF-β type I receptor, ALK1 mRNA expression level was 
decreased in the fibrotic samples compare to healthy subjects.  
 
 
 
Figure 4.1.  Expression analysis of TGF-β receptors in the lungs of transplant donors 
and IPF patients. 
Transforming growth factor β receptor mRNA expression was analysed by semi-quantitative RT-
PCR in homogenates from healthy lungs (donor; n=5) and lungs from IPF (n=6) patients. The RNA 
was isolated from the lungs directly frozen after explantation. Heat shock protein 70 (HSC) was 
used as the loading control. 
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4.1.2. Expression analysis of Smads by semi-quantitative PCR 
To further investigate potential changes in the levels of the TGF-β system 
components in human lungs, mRNA expression of intracellular mediators, Smads, in 
human lung tissue was analysed. The RNA was isolated from homogenates of transplant 
donors and IPF patients, previously used to assess TGF receptor expression. The mRNA 
levels of Smads were determined by semi-quantitative RT-PCR (Figure 4.2.). No changes 
in the expression were observed for Smads, except for Smad3 and Smad4 mRNA 
expression levels, which were decreased in the fibrotic samples compared to healthy 
donors.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.  Expression analysis of Smads in lungs of transplant donors and IPF 
patients. 
Smads mRNA expression was analysed by semi-quantitative RT-PCR in homogenates from 
healthy lungs (donor; n=5) and lungs from IPF (n=6) patients. RNA was isolated from the lungs 
directly frozen after explantation. Heat shock protein 70 (HSC) was used as the loading control,   
α-SMA was used as the positive control for fibrotic samples. 
 
 
4.1.3. Expression analysis of TGF-β receptors and Smads by 
quantitative PCR 
To confirm the semi-quantitative RT-PCR results, the mRNA expression level of 
TGF-β receptors and intracellular mediators, Smads, in human lung tissues were 
analysed. The RNA was isolated from human lung homogenates of transplant donors 
and IPF patients. Quantitative real-time PCR (Figure 4.3.) was used to determine the 
mRNA levels of receptors and Smads. Of all genes investigated, the type I TGF-β 
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receptor ALK1 (Ct of 1.28 and 3.11 in IPF and controls, respectively) exhibited 
significantly lower expression levels in IPF lungs. No evidence of altered Smad3 mRNA 
expression was detected by quantitative PCR in fibrotic samples, as detected by semi-
quantitative PCR (Figure 4.2.) 
 
A. 
 
B.  
 
 
 
 
 
 
 
 
 
Figure 4.3.  Expression analysis of TGF-β receptors and Smads in lungs of transplant 
donors and IPF patients. 
Transforming growth factor β receptors (A) and Smads (B) mRNA expression was analysed by 
quantitative real-time PCR in homogenates from healthy lungs (donor) and lungs from IPF 
patients. Values are represented as mean  S.E.M. (n=12). Statistically significant differences of   
p ≤ 0.01 (by Student’s t-test) are marked by *. 
 
 
4.1.4. Expression analysis of TGF-β target genes 
There are many target genes regulated by TGF-β. Among them are genes 
encoding proteins involved in the activation of fibroblasts, driving the production of ECM, 
and are, therefore, crucial for the pathogenesis of IPF. α-Smooth muscle actin and 
collagen type I (COL1A1) have been identified as the main participants in this disease, 
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and the expression levels of these proteins in human lung tissue were assessed. 
Additionally, the expression pattern of the target genes of TGF-β/ALK1 and TGF-β/ALK5 
pathways, Id1 and PAI1, respectively, were analysed. The mRNA levels of target genes 
were determined by quantitative PCR (Figure 4.4.).  
As expected, the mRNA levels of α-SMA (Ct of 1.7 and -0.2 in IPF and controls, 
respectively) and COL1A1 (Ct of 5.5 and 1.9 in IPF and controls, respectively) were 
significantly elevated in fibrotic samples. The mRNA expression levels of Id1 (Ct of 4.3 
and 5.1 in IPF and controls, respectively) and PAI1 (Ct of 2.0 and 1.1 in IPF and 
controls, respectively) revealed similar patterns of expression as ALK1 and ALK5, 
respectively in human lung tissue. 
 
 
Figure 4.4.  Expression analysis of TGF-β target genes in lungs of transplant donors and 
IPF patients. 
Transforming growth factor β target genes mRNA expression was analysed by quantitative real- 
time PCR in lung homogenate from healthy lungs (donor) and lungs from IPF patients. Values are 
represented as mean  S.E.M. (n=6). Statistically significant differences of p ≤ 0.01 and p ≤ 0.02 
(by Student’s t-test) are marked by * and **, respectively. 
 
 
 
 
4.2. Localisation of ALK1 and ALK5 in human lungs 
Previous results suggested a decrease in ALK1 mRNA expression in total lung 
homogenates from transplant donors and IPF patients. In order to verify ALK1 expression 
patterns in lung tissue, immunohistochemistry was performed on the sections obtained 
from healthy and fibrotic patients (Figure 4.5.). Moreover, it was examined whether the 
expression was specifically localised to particular cell types in the human lung.  
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Figure 4.5.  Localisation of ALK1 and ALK5 in tissue sections from the lungs of 
transplant donors and IPF patients. 
Paraffin-embedded lung sections from healthy (donor) and IPF patients were stained for ALK1, 
ALK5 (A) and α-SMA (B), as indicated. The IgG control (B) was performed as the primary 
antibody control. The pictures are representative of three independent experiments. 
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Figure 4.5.  Localisation of ALK1 and ALK5 in tissue sections from the lungs of 
transplant donors and IPF patients. 
Paraffin-embedded lung sections from healthy (donor) and IPF patients were stained for ALK1, 
ALK5 (A) and α-SMA (B), as indicated. The IgG control (B) was performed as the primary 
antibody control. The pictures are representative of three independent experiments. 
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Activin receptor-like kinase 5 was localised widely to endothelial cells, bronchial 
and alveolar epithelial cells, smooth muscle cells, as well interstitial fibroblasts, whereas 
ALK1 was localised mainly to endothelial cells, and to a certain extent, to epithelial cells, 
and to the interstitial regions which were α-SMA positive. Furthermore, ALK1 localised to 
cells that also showed localisation of α-SMA which stains interstial regions representing 
activated myofibroblasts. On comparing donors with fibrotic sections, ALK1 staining 
appears to be highly expressed in IPF than in donors, but this is not the case since 
immunohistochemistry is not a quantitative method and is widely applicable for 
determining cell specific localisation of proteins of interest. 
 
 
 
 
4.3. Analysis of the expression of TGF-β system 
components in primary human cells and cell lines 
4.3.1. Expression analysis of TGF-β system components in 
primary human cells 
4.3.1.1. Expression analysis of TGF-β system components and target genes 
in primary human fibroblasts 
As immunohistochemical results indicated the localisation of ALK1 in lung fibrotic 
foci, further investigations were performed in order to examine the expression of this 
receptor and other TGF-β system components as well as the target genes in human 
primary lung fibroblasts - the key cell type responsible for increased collagen deposition 
during lung fibrosis. Therefore, isolation of mRNA was carried out using primary 
fibroblasts derived from the lungs of healthy and IPF patients. The mRNA expression 
analysis was performed by quantitative real-time PCR (Figure 4.6.).  
As expected, expression levels of ALK1 (Ct of -3.2 and -1.5 in IPF hFB and 
donor hFB, respectively) was significantly downregulated in the fibrotic primary human 
fibroblasts. The other TGF-β receptors and Smads did not show any significant changes, 
except for Smad1 (Ct of -1.2 and 0.2 in IPF hFB and donor hFB, respectively) revealing 
downregulation in the fibrotic fibroblasts, but these differences were not significant. The 
mRNA expression level of target genes, α-SMA and COL1A1, was increased, but not 
significantly, in the fibrotic fibroblasts. The expression level of Id1 and PAI1 exhibit the 
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similar pattern of expression as in the lung homogenates, although the mRNA relative 
expression units (Ct) were different in both of these experiments. 
 
A. 
 
 
B. 
 
 
 
 
 
 
 
 
C. 
 
 
 
 
 
 
 
 
Figure 4.6.  Expression analysis of TGF-β system components in primary fibroblasts 
from the lungs of transplant donors and IPF patients. 
Transforming growth factor β receptors (A), Smads (B) and the TGF-β target genes (C) mRNA 
expression was analysed by quantitative real-time PCR in the fibroblasts isolated from healthy 
(donor) and fibrotic (IPF) human lungs. Values are represented as mean  S.E.M. (n=3). 
Statistically significant differences of p ≤ 0.05 (by Student’s t-test) are marked by *. hFB – human 
fibroblasts. 
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4.3.1.2. Expression analysis of TGF-β system components in pSMC, EpC 
and HUVEC 
The mRNA expression of ALK1 in the primary fibroblasts was found to be 
attenuated in lung fibrosis. To further verify the expression of ALK1 in other human 
primary cells, the endogenous expression level of TGF-β receptors was examined in 
human primary pulmonary smooth muscle cells (pSMC), primary epithelial cells (EpC) 
derived from donor and fibrotic human lungs, and human umbilical vein endothelial cells 
(HUVEC). The endogenous level of TGF-β target genes was verified in pSMC and 
HUVEC. The mRNA expression analysis was performed by quantitative PCR         
(Figure 4.7.). 
 
A.  
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
Figure 4.7.  Endogenous mRNA expression analysis of TGF-β receptors and target 
genes in pulmonary smooth muscle cells, human umbilical vein endothelial 
cells and epithelial cells from transplant donors and IPF patients. 
The mRNA expression levels of the TGF-β receptors (A) and the TGF-β target genes (B) were 
analysed by quantitative real-time PCR in the pSMC, EpC. Human umbilical vein endothelial cells 
serve as the positive control for ALK1 and endoglin mRNA expression. Values represent mean  
S.E.M. (n=4), except for donor EpC (n=1). 
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The expression of ALK1 in the lung pSMC and EpC is generally low (Ct of 1.1, 
0.9 and 0.8 in pSMC, healthy EpC and fibrotic EpC, respectively) compared to HUVEC 
(Ct of 5.9) which are known to have a very high level of endogenous ALK1 and 
endoglin. The other receptors are expressed at the high levels implying that the TGF-β 
signalling receptors are present in all these cells. The level of Id1 (Ct of 2.7 and 2.3 in 
HUVEC and pSMC, respectively) is not as high as expected when compared to the level 
of ALK1 in this cell type. The low levels of α-SMA (Ct of -0.9) and COL1A1 (Ct of -4.5) 
mRNA expression in HUVECs in comparison to pSMC (Ct of 3.9 for α-SMA and 10.1 for 
COL1A1) confirms that HUVECs does not play such a big role in ECM production as 
pSMC do.  
 
 
4.3.2. Expression analysis of TGF-β system components in 
human cell lines  
4.3.2.1. Expression analysis of TGF-β system components in IMR-90 cells 
Due to the limited amount of the freshly isolated primary fibroblasts, the mRNA 
expression of TGF-β system components was analysed in the human lung fibroblast cell 
lines, IMR-90 and HFL1. The IMR-90 cell line is a human lung fibroblast cell line derived 
from a caucasian female. The mRNA expression level of TGF-β type I receptors, TGF-β 
type II receptor, endoglin and TGF-β target genes in IMR-90 cells was analysed by 
quantitative real-time PCR (Figure 4.8.). 
As expected, the mRNA expression levels of most of these genes were similar to 
those seen in primary fibroblasts, except for endoglin and Id1. Endoglin expression (Ct 
of 2.4 and -3.4 in IMR-90 and donor primary fibroblasts, respectively) was higher in    
IMR-90 than in primary fibroblasts, and Id1 expression (Ct of -4.0 and 1.8 in IMR-90 and 
donor primary fibroblasts, respectively) was very low in IMR-90 in comparison to the 
expression level seen in primary fibroblasts.  
 
 
 
 
 
 
Results  48 
 
 
 
 
 
 
 
 
 
 
Figure 4.8.  Endogenous mRNA expression analysis of TGF-β receptors and target 
genes in the human lung fibroblast cell line, IMR-90. 
The mRNA expression levels of the TGF-β receptors and the TGF-β target genes were analysed 
by quantitative real-time PCR in IMR-90 cell. Values are represented as mean  S.E.M. (n=3).  
 
 
4.3.2.2. Expression analysis of TGF-β system components in HFL1 cells 
The mRNA expression levels of TGF-β system components were analysed in 
another human lung fibroblast cell line, HFL1, which are foetal lung fibroblasts. The 
mRNA expression levels of ALK1, ALK5, TGF-β type II receptor, endoglin and TGF-β 
target genes in HFL1 cells were analysed by quantitative real-time PCR (Figure 4.9.). The 
expression levels of investigated genes displayed the same pattern in HFL1 as the 
mRNA expression levels in IMR-90 cells.  
 
 
 
 
 
 
 
 
 
 
Figure 4.9.  Endogenous mRNA expression analysis of TGF-β receptors and target 
genes in the human lung fibroblast cell line, HFL1. 
The mRNA expression levels of the TGF-β receptors and the TGF-β target genes were analysed 
by quantitative real-time PCR in the HFL1 cells. Values are represented as mean  S.E.M. (n=3).  
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4.4. TGF-β signalling activity in HFL1 and IMR-90 
fibroblast cell lines 
4.4.1. Analysis of the phosphorylation of Smads in HFL1 and 
IMR-90 fibroblast cell lines 
Previous results displayed the presence of TGF-β signalling components in    
IMR-90 and HFL1 cell lines at the mRNA level. The activation of TGF-β signalling leads 
to the phosphorylation of the downstream mediators: the Smads. To investigate a 
signalling in IMR-90 and HFL1 cells, cells were stimulated with TGF-β1 or BMP2 ligands 
for 30 s or 2 h, and phosphorylated Smad proteins were analysed by immunoblotting 
(Figure 4.10.).  
Both TGF-β and BMP signalling pathways are activated in IMR-90 and HFL1. The 
phosphorylation of Smad2 and Smad1/5/8 occurs at the earliest time point, after 30 s of 
TGF-β1 and BMP2 stimulation, respectively. Surprisingly, after TGF-β1 stimulation the 
phosphorylation of BMP-specific Smads was visible, indicating the presence of an 
additional pathway, ALK1/Smad1/5/8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10.  TGF-β signalling activity in human fibroblast cell lines. 
Phosphorylation of Smad2 and Smad1/5/8 in the human fibroblast cell lines, IMR-90 and HFL1, 
after TGF-β1 and BMP2 stimulation for 30 s and 2h. Smad1/2/3, total amount of Smad1/2/3 
proteins level, serves as a loading control. The images are representative of three independent 
experiments. 
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4.5. siRNA knockdown of ALK1 and ALK5 in HFL1 and 
IMR-90 fibroblast cell lines 
4.5.1. Knockdown of ALK1 in HFL1 and IMR-90 fibroblast cell 
lines 
Attenuated levels of ALK1 were observed in the fibrotic samples of the total lung 
homogenates and the primary fibroblasts, as well in the lung fibroblast cell lines. To 
investigate, whether the downregulation of ALK1 might cause the excessive ECM 
production leading to the IPF, siRNA-mediated knockdown of the TGF-β type I receptor 
was performed. The fibroblast cell lines were transfected with increasing amounts of 
siRNA directed against human ALK1. The knockdown efficiency was analysed by 
quantitative real-time PCR (Figure 4.11.) and the percent gene knockdown was 
calculated as described in the chapter 3.2.11.4.  
 
A.  
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
Figure 4.11.  Analysis of siRNA-mediated knockdown of ALK1. 
The cells were transfected with the increasing concentrations of siRNA specific for the ALK1 gene 
(10, 25, 50 and 100 nM) for 36 h and the ALK1 and ALK5 mRNA expression levels were analysed 
by quantitative real-time PCR in the human fibroblasts cell lines, HFL1 (A) and IMR-90 (B). Values 
represent mean  S.E.M. (n=3). Statistically significant differences of p ≤ 0.0005 in A and              
p ≤ 0.005 in B (by Student’s t-test) are marked by *.  
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Activin receptor-like kinase 1 mRNA expression was significantly downregulated 
by siRNA knockdown technology, in both IMR-90 and HFL1 cells. The best knockdown 
(91.2%) in HFL1 cells was seen at a concentration of 10 nM of siRNA, but the other 
concentrations were also effective (25 nM – 90.7%, 50 nM – 90.7% and 100 nM – 
90.1%). Similarly, in IMR-90 cells the best knockdown was observed at a siRNA 
concentration of 10 nM (94.4%). The percent knockdown with other siRNA concentrations 
was as effective as in HFL1 cells, at a concentration of 25 nM – 92.9%, 50 nM – 92.6% 
and at 100 nM – 92.7%. Activin receptor-like kinase 5 mRNA expression was not 
disturbed by any of siRNA targeting ALK1. 
 
 
4.5.2. Knockdown of ALK5 in HFL1 and IMR-90 fibroblast cell 
lines 
Activin receptor-like kinase 5 is a receptor co-existing with ALK1 and as reported 
79; both play well-balanced roles in endothelial cells. The siRNA-mediated gene 
knockdown of ALK5 was performed to investigate the role of the second TGF-β type I 
receptor in contrast to ALK1 in the process of ECM production. The IMR-90 and HFL1 
were transfected with increasing amounts of siRNA directed against human ALK5. The 
knockdown efficiency was analysed by quantitative real-time PCR (Figure 4.12.) and the 
percent gene knockdown was calculated as mentioned in section 3.2.11.4.  
Activin receptor-like kinase 5 mRNA was significantly downregulated by siRNA 
oligonucleotides, in both IMR-90 and HFL1 cells. In HFL1, the best concentration was   
10 nM (81.9% of gene knockdown), but other concentrations were equally good at 
knocking down the expression of ALK5, for example 10 nM. At 25 nM of siRNA the 
percent knockdown was 81.6%, at 50 nM – 79.0% and at 100 nM – 79.2%. In IMR-90 
cells, the siRNA effectiveness was calculated as follows: 10 nM – 85.9%, 25 nM – 78.2%, 
50 nM – 84.7% and 100 nM – 84.7%. In both cases, the minimal concentration of 10 nM 
was significant and sufficient to knockdown more than 80% of the ALK5 mRNA 
expression, similar to the effect of ALK1 siRNA knockdown. Activin receptor-like kinase 1 
mRNA expression was not changed during the siRNA treatment of ALK5 in both 
fibroblast cell lines. 
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Figure 4.12.  Analysis of siRNA-mediated knockdown of ALK5. 
The cells were transfected with the increasing concentrations of siRNA specific for the ALK5 gene 
(10, 25, 50 and 100 nM) for 36 h and the ALK1 and ALK5 mRNA expression levels were analysed 
by quantitative real-time PCR in the human fibroblasts cell lines, HFL1 (A) and IMR-90 (B). Values 
represent mean  S.E.M. (n=3). Statistically significant differences of p ≤ 0.005 (by Student’s t-
test) are marked by *.  
 
 
 
 
4.6. Effect of siRNA-mediated downregulation of ALK1 
on ECM deposition in HFL1 and IMR-90 fibroblasts 
4.6.1. Expression analysis of TGF-β receptors and target genes 
after knockdown of ALK1 in fibroblast cell lines 
Whether a direct causal relationship existed between downregulation of ALK1 and 
the process of ECM deposition in human fibroblasts was next examined. From the 
previous results, there is a very effective siRNA-mediated knockdown of both, ALK1 and 
ALK5, in HFL1 and IMR-90 fibroblasts. The HFL1 and IMR-90 cells were transfected with 
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10 nM of siRNA specific for human ALK1 for 48 h and stimulated with TGF-β1 for an 
additional 24 h. The mRNA expression levels of ALK1, ALK5, TGF-β type II receptor, 
endoglin and TGF-β target genes in HFL1 cells were analysed by quantitative real-time 
PCR (Figure 4.13.).  
 
A. 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13.  Expression analysis of TGF-β receptors and target genes after knockdown 
of ALK1 in fibroblast cell lines.  
Cells were transfected with 10 nM of siRNA specific for the ALK1 gene for 48 h and stimulated 
with TGF-β1 for an additional 24 h. The mRNA expression levels of the TGF-β receptors and the   
TGF-β target genes were analysed by quantitative reverse transcriptase PCR in the human 
fibroblasts cell lines, HFL1 (A) and IMR-90 (B). Values represent mean  S.E.M. (n=4). 
Statistically significant differences of p ≤ 0.05 and p ≤ 0.005 (by Student’s t-test) are marked by * 
and **, respectively. The knockdown level was more than 80% in both cell lines.  
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As shown previously, there was a significant knockdown of ALK1 without affecting 
the ALK5, TGF-βRII and endoglin mRNA levels. COL1A1 mRNA expression in IMR-90 
cells was significantly downregulated after siRNA treatment (Ct of 10.6 and 8.9 in 
negative siRNA and siALK1 without TGF-β1 stimulation, respectively), and was partially 
rescued by TGF-β1 stimulation, but was still significantly lower in comparison to the 
negative siRNA-treated cells (Ct of 10.9 and 10.2 in negative siRNA and siALK1 with 
TGF-β1 stimulation, respectively). The results obtained with HFL1 cells were not 
significant, but reveal the same pattern of COL1A1 gene expression without TGF-β1 
stimulation (Ct of 10.4 and 8.4 in negative siRNA and siALK1, respectively), as well as 
after TGF-β1 treatment (Ct of 10.6 and 9.6 in negative siRNA and siALK1, respectively). 
The mRNA expression levels of PAI1 and α-SMA were not altered by siRNA-mediated 
knockdown of ALK1, although TGF-β1 was a very potent stimulator of expression of 
these genes independently of siALK1. The Id1 mRNA level was significantly changed 
during the siRNA transfection and TGF-β1 stimulation, reflecting exactly the level of ALK1 
mRNA during the same treatments. 
 
 
4.6.2. Effect of ALK1 knockdown on TGF-β1-induced collagen 
deposition in fibroblast cell lines 
Increased collagen deposition, largely mediated by enhanced TGF-β1 signalling, 
represents the pathological hallmark of fibrosis 19. Additionally, TGF-β1 induces the 
differentiation of myofibroblasts and the collagen production by these cells 31. Previous 
results indicated the significantly increased level of COL1A1 expression upon TGF-β1 
stimulation and ALK1 knockdown. Therefore, an investigation was performed to 
determine collagen deposition in the presence of the ALK1 siRNA in human fibroblast cell 
lines. Cells were transfected with siRNA against ALK1 or ALK5 for 48 h and subsequently 
stimulated with TGF-β1 (2 ng/ml) for up to 24 h, and cellular collagen content was 
analysed by Sircol assay (Figure 4.14.).  
The TGF-β1-induced increase in collagen production (35.12 ng/ml and 42.85 
ng/ml of collagen content in neg siRNA treated cells without or with TGF-β1 stimulation, 
respectively) was significantly attenuated by siRNA-mediated knockdown of ALK1 in 
HFL1 cells (42.85 ng/ml and 32.81 ng/ml of collagen content in neg siRNA or siALK1 
treated cells after TGF-β1 stimulation, respectively). No changes in COL1A1 levels upon 
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siRNA treatment were detected in IMR-90 cells. The collagen production was not altered 
by ALK5 knockdown in both cell types.  
 
A. 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
 
 
 
 
 
 
Figure 4.14.  Effect of ALK1 siRNA knockdown on TGF-β1-induced cellular collagen 
production in fibroblast cell lines.  
The cells were transfected with 10 nM of siRNA specific for the ALK1 gene for 48 h and stimulated 
with TGF-β1 for an additional 24 h. Cellular collagen content was analysed by Sircol assay in the 
human fibroblast cell lines, HFL1 (A) and IMR-90 (B). Values represent mean  S.E.M. (n=3). 
Statistically significant differences (p ≤ 0.05, student’s t-test) are marked by *. 
 
 
 The collagen deposition is characterised not only by cellular collagen production, 
but also by collagen secretion into the extracellular space leading to the excessive ECM 
protein accumulation in the fibrotic lung tissue 40. Therefore, the determination of secreted 
collagen level in the presence of the ALK1 siRNA in human fibroblast cell lines was 
performed. Cells were transfected with ALK1 siRNA for 48 h and stimulated with TGF-β1 
(2 ng/ml) for an additional 24 h, and cell culture media were collected. Collagen content 
in the cell culture supernatant was analysed by Sircol assay (Figure 4.15.). 
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 The collagen content in the cell culture media of HFL1 cells did not reveal any 
changes after ALK1 ablation, and treatment with TGF-β1. However, the collagen levels in 
the cell culture supernatants of IMR-90 cells was decreased by ALK1 knockdown, and 
was significantly reversed after TGF-β1 stimulation (32.88 ng/ml and 65.31 ng/ml 
collagen in the cell culture supernatants of the cells transfected with siALK1 without or 
with TGF-β1 stimulation, respectively).  
 
A.  
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 4.15.  Effect of ALK1 siRNA knockdown on TGF-β1-induced collagen secretion by 
fibroblast cell lines.  
The cells were transfected with 10 nM of siRNA specific for the ALK1 gene for 48 h and stimulated 
with TGF-β1 for an additional 24 h. Cell culture media from the HFL1 (A) and IMR-90 (B) cultures 
were collected and secreted collagen content was analysed by Sircol assay. Values represent 
mean  S.E.M. (n=3). Statistically significant differences of p ≤ 0.05 (by Student’s t-test) are 
marked by *. 
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5. Discussion 
5.1. Involvement of ALK1 in lung diseases  
Recently, many reports have shown an interest in ALK1 expression and activity, in 
the cooperation of ALK1 and ALK5 receptors, but few publications have addressed the 
impact of ALK1 on lung diseases. Activin receptor-like kinase 1 is linked to the autosomal 
dominant vascular disorder, haereditary hemorrhagic telangiectasia (HHT) type 2 103, 104. 
Haereditary hemorrhagic telangiectasia is a multisystemic vascular dysplasia 
characterised by dilated vessels or telangiectases on mucocutaneous surfaces and 
arteriovenous malformations (AVMs) in the lung, liver and brain 105. The ACVRL1 (ALK1) 
gene was found to be mutated in HHT2. Haereditary hemorrhagic telangiectasia results 
in secondary pulmonary artery hypertension (PAH) 106. The ALK1 mutations associated 
with primary pulmonary hypertension (PPH) are also of varying types and found 
throughout the gene 107. Hypertension causes structural changes in the arteries, including 
hypertrophy of vascular smooth muscle cells, collagen and fibronectin accumulation, and 
destruction of elastic fibers. In the lung, in vascular smooth muscle cells, endothelial cells, 
and fibroblasts, TGF-β1 increases the synthesis of ECM proteins, such as fibronectin,    
α-SMA, collagens, and PAI1. All this information points to a specific role for TGF-β 
signalling in the ECM protein production, specifically for the type I receptors, ALK1 and 
ALK5, which are found to be the main players in the homeostasis of endothelial cells and 
vascular fibrosis 67, but nothing is known about the role of ALK1 in the pulmonary fibrosis.  
 
 
 
 
5.2. TGF-β signalling components in fibrotic human 
lungs 
5.2.1. TGF-β receptors, Smads and target gene expression 
patterns 
In the present study, the TGF-β signalling components, such receptors, 
intracellular mediators and target genes, were analysed in the context of IPF. All TGF-β 
members investigated were present in the lungs of healthy subjects and patients with 
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IPF, and no changes between them were found (Figure 4.1., 4.2., 4.3.). All aspects of the 
fibrotic processes have been shown to be regulated by TGF-β 108. No other growth factor 
has as many different activities contributing to matrix accumulation, as does TGF-β. The 
TGF-β is present in the normal lungs, suggesting a role in the regulation of normal 
physiological processes to maintain lung homeostasis 109. To a large extent, TGF-β 
mediates tissue remodelling and repair 110-112, and is present in lung diseases and 
systemic diseases, for example giant-cell interstitial pneumonia, histiocytosis, 
scleroderma, systemic lupus erythematosus, cystic fibrosis 113, chronic obstructive lung 
disease 114, and idiopathic pulmonary fibrosis 115-118. Transforming growth factor β 
signalling is a very prominent and one of the most studied pathway in the context of lung 
fibrosis.  
The Smad3 RNA expression was not changed when assessed by quantitative 
PCR, despite the fact that Smad3 was downregulated when assessed by 
semiquantitative PCR (Figure 4.2. and 4.3.). These discrepancies might be explained by 
the technical difficulties performing the semiquantitative PCR. Generally, it is known that 
Smads are involved in the regulation of COL1, COL3 and COL4 gene expression, and 
coordination of increased levels of these collagens in the media. Overexpression of 
Smad2, Smad3 and Smad4 increases the production of all collagen types 119 Although it 
is reported that in skin fibrosis, treatment of myofibroblasts with TGF-β1 inhibits 
expression of Smad3, but not Smad2 120. Conversely, the TGF-β/Smad3 pathway is the 
key regulator of the progression of IPF, because the progression of IL-1β-induced 
inflammation toward fibrosis is Smad3 dependent, and it develops only in wild type 
control mice and not in Smad3 null mice 121. In another study, mice deficient in Smad3 
demonstrated suppressed type I procollagen mRNA expression and reduced 
hydroxyproline content in the lungs, compared with wild-type mice treated with bleomycin. 
Furthermore, loss of Smad3 greatly attenuated the morphological fibrotic responses to 
bleomycin in the mouse lungs 122. Surprisingly, however, production of ECM was 
unaffected during cutaneous wound healing in Smad3 null-mice, suggesting the 
existence of a Smad3-independent mechanism involved in the tissue repair by dermal 
fibroblasts 123. 
No evidence has been provided concerning the implication of ALK3 and ALK6 in 
the pathogenesis of lung fibrosis. It is known that the BMP7 ligand has an anti-fibrotic 
effect in renal fibrosis, which is mediated by p38/Smad1 pathways in a dose-dependent 
manner 124, 125. BMP7 drives its signal via ALK6, but the exact molecular mechanism of 
this action in the lung has not yet been elucidated.  
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However, significant changes were observed at the ALK1 mRNA expression level. 
There are no publications reporting the role of this specific type I TGF-β receptor in IPF. 
One of the characteristics of fibrotic lesions is the aberrant expression of TGF-β 
receptors. For instance, an increased ratio of TGF-βRI to TGF-βRII expression levels has 
been observed in liver fibrosis 126 and scleroderma 127, while increases in the expression 
of TGF-βRI has been observed in kidney fibrosis 128. In addition, a previous study has 
demonstrated that constitutively elevated expression levels of CTGF in scleroderma 
fibroblasts are Smad2/3-independent 129. These findings suggest that overproduction of 
matrix in fibrosis might be, at least in part, due to the alternative activation of TGF-β 
signalling.  
Recently, a study in scleroderma fibroblasts was performed, and the authors 
found that collagen protein production in these cells was resistant to inhibition by ALK5 
kinase inhibitors. Additionally, it was concluded that TGF-βRI-dependent induction of 
fibrotic processes does not involve Smad2/3, and is activated and mediated by 
ALK1/Smad1 and ERK1/2 pathways 130. Similarly, TGF-β signalling via activation of 
ALK1/Smad1 pathway and subsequent upregulation of the Id1 gene has been shown to 
contribute to transdifferentiation of hepatic stellate cells into myofibroblast during fibrosis 
processes in the liver 131. These recent studies strongly suggest that activation of 
ALK1/Smad1 signalling may play an important role in the development of organ fibrosis, 
and needs further investigation.  
According to many reports, the expression of COL1 and α-SMA is highly 
upregulated during IPF pathogenesis 30, 66, 72, 132, and it has been shown that mRNA levels 
of COL1A1 and α-SMA has been significantly increased (Figure 4.4.). Similar results 
were obtained with studies on the mRNA expression of plasminogen activator inhibitor 1 
(PAI1). The PAI1 is known to be the major physiological inhibitor of tissue-type and 
urokinase-type plasminogen activator. These two molecules convert inactive 
plasminogen into its fibrin-degrading form, plasmin. Plasma and tissue concentrations of 
PAI1 are extremely low under normal circumstances, but increase under pathological 
conditions, for example organ fibrosis. This increase is mediated by many factors, 
including TGF-β 133-136. Moreover, Id1 mRNA levels were significantly lower in fibrotic 
samples compared to healthy subjects. The Id1 protein is a helix-loop-helix protein 
inhibitor of differentiation 1, which lacks the basic DNA binding domain and functions as 
naturally-occurring dominant-negative inhibitor of gene transcription, by forming 
nonfunctional heterodimers with basic helix-loop-helix proteins 137. It has been found that 
mice lacking the gene for Id1 have increased susceptibility to bleomycin-induced lung 
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fibrosis, demonstrated by elevated levels of collagen deposition and fibrogenesis 138. 
However, Id1 was found to be highly expressed by myofibroblasts within fibroblastic foci 
in response to TGF-β1, and further behaved like a typical immediate-early gene 139.  
 
5.3. ALK1 expression in fibroblasts 
5.3.1. Cell type localisation of ALK1 
Activin receptor-like kinase 1 was reported to be specifically expressed in 
endothelial cells, at the active sites of angiogenesis and the specific sites of epithelial-
mesenchymal cells 80, 91. Recently, the ALK1 expression was shown to be present in the 
human chondrocytes 140.  
The immunohistochemical analysis of the ALK1 localisation in paraffin-embedded 
human tissue sections (Figure 4.5.) demonstrated the presence of ALK1 in bronchial and 
alveolar epithelial cells, smooth muscle cells, endothelial cells, and the interstitial areas, 
which were α-SMA positive, suggesting activated interstitial fibroblasts. Activated 
fibroblasts, called myofibroblasts, are α-SMA positive and posses a contractile phenotype 
141. These results are of importance since the α-SMA-positive interstitial regions are the 
places of the activated (myo)fibroblasts and the localisation of ALK1 to that cell type is 
novel, and has not been reported previously. Activin receptor-like kinase 5 was stained in 
all lung cell types, as it has been indicated that ALK5 receptor is expressed 
predominantly in different tissues and cell types, including lung. The 
immunohistochemical staining is a non-quantitative method; therefore, it has been difficult 
to quantify the expression level of ALK1 and ALK5 in healthy and fibrotic tissue sections  
 
 
5.3.2. Lung cell type specific expression pattern of ALK1 
5.3.2.1. ALK1 mRNA expression in primary human fibroblasts 
The mRNA expression of ALK1 was significantly lower in primary human 
fibroblasts isolated from the lungs of fibrotic patients, compared with donor fibroblasts 
(Figure 4.6.). Moreover, the mRNA levels of other receptors and Smads were not 
altered, except for Smad1, which exhibited decreased mRNA levels in fibrotic fibroblasts. 
The Smad1, together with Smad5 and Smad8, is a specific mediator of ALK1/TGF-β 
signalling 142. Nevertheless, the mRNA expression analysis does not reflect the activity of 
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the ALK1 pathway, which in this case might suggest the attenuation of ALK1/Smad1 
signalling.  
Activated fibroblasts during fibrogenesis lead to increased production of ECM 
proteins, as is shown by elevated levels of COL1A1 and α-SMA mRNA in fibrosis-
derived fibroblasts (Figure 4.6.). The lack of statistical significance and large deviations 
in the case of donor fibroblasts might be explained as: a) there was no information about 
whether healthy patients were treated with some medication, b) it is known only that the 
patients were not smokers, c) there are no reports that these patients have other 
underlying lung diseases. Culture conditions and methods might effect some 
characteristic of the cells 143, for instance the absence of significant changes in α-SMA 
and COL1A1 between primary fibroblasts from healthy subjects and patients with IPF. 
Characteristic of fibroblasts in vivo are different from those of in vitro cultured cells. The 
number of passages is another factor that influences cells 144, 145. Additionally, different 
results may be due to different characteristic of patients from whom the lung specimens 
were obtained, including the diagnosis of disease, age, and clinical status of the 
subjects. The pathological patterns of the cases used in the present study exhibited a 
UIP-type histopathology with the clinical manifestation of IPF. 
It is known that under the stimulation of growth factors and of newly synthesised 
ECM components, the fibroblasts evolve toward the intermediate stage of proto-
myofibroblasts, and further toward the differentiated myofibroblasts, which are 
characterised by the expression of α-SMA 146 147. The importance of α-SMA expression 
as a marker of myofibroblastic modulation is currently well accepted. These α-SMA 
positive fibroblasts synthesise elevated levels of ECM components and matrix degrading 
proteases, which leads to excessive scarring in the diseased organ. The 
immunohistochemical study with antibodies specific for the propeptides of type I collagen 
have localised the cells extensively producing this collagen. In the normal lungs, the 
synthesis of collagen is sufficiently low that the fibroblasts remains unstained, whereas 
positive staining has identified fibroblasts activated to synthesise collagen type I as a 
consequence of disease 148.  
The mRNA levels of Id1 and PAI1 in primary fibroblasts was similar to the mRNA 
levels of these genes in the human lung homogenates of healthy and fibrotic patients 
(Figure 4.4. and 4.6.). The Id1 was reported to be robustly, although transiently, induced 
in fibroblasts by TGF-β1, which might initially delay myofibroblast differentiation, and 
raises the possibility that Id1 plays a part in determining fibroblast behaviour in the 
setting of fibrosis 139. The elevated PAI1 levels promote collagen deposition not by 
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inhibiting plasmin, but by stimulating migration of collagen-producing cells into the 
damaged tissue 149, and since the myofibroblasts are collagen-producing cells, the 
increased level of PAI1 mRNA appears in line with this idea.  
 
 
5.3.2.2. ALK1 mRNA expression in the other lung cell types 
The endogenous mRNA levels of TGF-β receptors and target genes in pulmonary 
smooth muscle cells (pSMC), and healthy and fibrotic epithelial cells (EpC) (Figure 4.7.) 
matched the immunohistochemical localisation of ALK1 and ALK5 (Figure 4.5.). The 
endogenous level of TGF-β target genes was verified in pSMC and HUVEC, but not in 
EpC due to the limitation of the freshly isolated primary cells.  
The observed pattern of ALK1 expression was novel, since most data have 
indicated the presence of ALK1 exclusively in endothelial cells, therefore, HUVECs 
served as a positive control for ALK1 and endoglin expression. The HUVEC expressed 
COL1A1 and α-SMA at low levels, although these cells were reported to facilitate the 
collagen deposition by human periodontal ligament fibroblasts (HPLFs) in the model of 
co-culture of HPLFs with HUVECs 150. Conversely, pSMC, which are involved in the 
remodelling processes in asthma, are α-SMA positive 151. Smooth muscle cells involved 
in atherosclerosis change phenotype from a contractile to synthetic, and deposit type I 
and III collagens, elastin and fibronectin 152. 
The mRNA level of ALK1 is very high in the HUVEC, whereas the level of Id1 is 
much more lower. It could be explained that Id1 is a specific, but not only one, target 
gene for ALK1/TGF-β signalling 153 and most importantly, we can not correlate directly the 
level of Id1 mRNA expression with mRNA level of ALK1 without knowing the activity level 
of that receptor. 
 
 
5.3.2.3. Active ALK1/TGF-β signalling in human lung fibroblast cell lines 
The ALK1 mRNA levels, as well as the other receptors and TGF-β pathway target 
genes, displayed a similar pattern of expression in both fibroblast cell lines (Figure 4.8. 
and 4.9.), as well as in the primary human fibroblasts (Figure 4.6.). Similarly, ALK1 was 
present at low level. However, both cell lines exhibited high levels of expression of the 
ECM genes COL1A1 and α-SMA, and the profibrotic PAI1.  
Transforming growth factor β1 has been demonstrated to active TGF-β signalling 
pathways via the phosphorylation of Smad2 at 30 min after stimulation, and lasting for up 
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to 2 h in both cell lines, HFL1 and IMR-90 (Figure 4.10.). Conversely, BMP2 activated the 
BMP signalling by phosphorylation of Smad1/5/8 in both fibroblasts. Suprisingly, TGF-β1 
was able to phosphorylate Smad1/5/8 as well, suggesting the presence of an active 
ALK1/TGF-β pathway in both cell lines in a similar fashion.  
The canonical TGF-β pathway functions via ALK5, and leads to the 
phosphorylation of intracellular Smad2/3 49. There is also increasing evidence for the 
activation of other signalling pathway downstream of TGF-β, the ALK1/Smad1/5 pathway, 
shown mostly in the endothelial cells 79, 80. Moreover, Smad-independent pathways 
involved in the TGF-β are active in many cell types and tissues 58, 154-156. The canonical 
BMP pathway acts via the phosphorylation of Smad1/5/8 157. However, recent studies 
have established that activation of the Smad1 pathway may represent a novel aspect of 
profibrotic TGF-β signalling that functions independently of the activation of the canonical 
Smad2/3 pathway, at least in the in vitro model of systemic sclerosis 130. Additionally, 
imatinib mesylate, an inhibitor of profibrotic effects of TGF-β in cultured cells and 
experimental models of fibrosis, was able to block TGF-β-induced activation of Smad1 
and ERK1/2 in control fibroblasts and induce phosphorylation of Smad1 and ERK1/2 in 
systemic sclerosis fibroblasts 158.  
Interestingly, there is a report demonstrating that in some cell types, TGF-β may 
induce Smad1 phosphorylation independently of the BMP type I receptors 159. The 
authors have suggested that TGF-β can significantly induce Smad1 phosphorylation in 
several non-endothelial cell lineages using chemical inhibitors specific for TGF-β type I 
receptors (ALK4/5/7) and BMP type I receptors (ALK1/2/3/6).  
A pathway for the canonical TGF-β signalling from the cell surface to the nucleus 
in response to the various ligands has been established. However, unexpected signalling 
outcomes, or even opposing biological outcomes of TGF-β signalling pathway, in the 
same cells, suggest that the signalling model is not quite as simple as first thought. The 
ALK1 pathway is one such examples, but signalling via the TGF-βRII/ALK1 complex is 
dependent on ALK5 kinase activity and endoglin, to result in Smad1/5 phosphorylation in 
response to TGF-β, and it has been proposed that ALK1 activation may inhibit 
ALK5/Smad2/3 signalling 80, 94. The TGF-β can induce Smad1 phosphorylation in a 
number of epithelial cells and fibroblasts via ALK5 and ALK2 and/or ALK3, which 
suggests a dependence on a BMP type I receptors 160. Another publication has presented 
similar results, where Smad1 phosphorylation in the mouse mammary epithelial cell line 
4T1 was strictly dependent on ALK5 kinase acivity, and the authors ruled out the 
involvement of BMP receptors using shRNA 161. Moreover, the specificity of type I 
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receptors for the canonical Smads is usually based on the L45 loop and phosphorylated 
GS motif, and on the L3 loop in the MH2 domain of the partner Smad 162-164. The authors 
suggested that ALK5 can directly contact Smad1 despite the assumed incompatible L45-
L3 pairing 159. To conclude, the key pathway leading to the phosphorylation of Smad1 by 
TGF-β involves ALK1, but additionally, options to activate Smad1 signalling, which could 
be completely independent on ALK1, exist.  
 
 
5.4. The effect of ALK1 on collagen deposition 
5.4.1. Effective ALK1 knockdown in fibroblasts 
To be able to mimic the situation in human lung homogenates and human primary 
fibroblasts, ALK1 and ALK5 mRNA expression was significantly and sufficiently silenced 
by siRNA technology (Figure 4.11. and 4.12.) in the HFL1 and IMR-90 fibroblast cell 
lines. Most importantly, the knockdown of ALK1 had no effect on the mRNA expression of 
ALK5, and ALK5 had no effect on ALK1 mRNA levels, suggesting that siRNA 
oligonucleotides used in the assay specifically recognise each type I receptor. 
 
 
5.4.2. The effect of ALK1 on COL1A1 mRNA expession 
From the previous results, the suggestion might be that the diminished levels of 
ALK1 could lead to the activation of fibroblasts, and subsequently to the elevated levels 
of collagen production and deposition. The ALK1 silencing lasted for 72 h and was more 
pronounced after TGF-β1 stimulation in both cell lines (Figure 4.13.) without affecting the 
mRNA level of ALK5, endoglin and TGF-βRII. The Id1, the specific target gene of ALK1, 
was downregulated in parallel with the knockdown of ALK1, and was more affected after 
TGF-β stimulation. The expression of PAI1 and α-SMA was significantly changed upon 
TGF-β1 stimulation, but independently of ALK1 siRNA-mediated knockdown. These 
alterations are also evident in the case of COL1A1 mRNA expression. The TGF-β1 had 
no effect on endogenous COL1A1 levels, but the siRNA specific for ALK1 attenuated the 
COL1A1 expression, which was restored almost to endogenous levels upon TGF-β1 
treatment. This might imply that in the absence of ALK1, ALK5 signalling might by 
preferred to induce collagen gene transcription, although the lack of ALK1 abolished the 
amount of COL1A1 mRNA. To be able to distinguish precisely between the ALK1 and 
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ALK5 signalling, the same experiment with the knockdown of ALK5 might be of 
importance.  
Collagen types I and II are the most abundant proteins found in the airways, blood 
vessels and alveolar septa. These collagens are synthesised by many cell types, but 
predominantly by mesenchymal cells: fibroblasts, myofibroblasts and smooth muscle 
cells 165. There is considerable evidence implicating TGF-β1 in the pathogenesis of IPF 
166. Moreover, TGF-β is one of the most potent profibrotic mediators, produced by many 
cell types, which are known to promote fibroblast proliferation, migration, collagen 
synthesis and differentiation 165, 167, 168. Surprisingly, COL1A1 mRNA was generally very 
highly expressed in the fibroblasts, but was not changed after TGF-β1 stimulation  
(Figure 4.13.). Conversely, PAI1 and α-SMA were very responsive to TGF-β1. The 
explanation to that confused results would be either the low concentration of ligand 
efficient to increase the already very high level of COL1A1, or the short stimulation time 
for the same action, although these concentration and stimulation time were always 
efficient in many other experiments. Longer stimulation with TGF-β1 caused cell death. 
Recently it has been reported that ALK1 inhibits, while ALK5 potentiates, TGF-β1-
induced Smad3-dependent transcriptional activity, and the expression of the ECM 
components PAI1, fibronectin and collagen type II in human chondrocytes 140. Activin 
receptor-like kinase 1 may exert its inhibitory effect downstream of Smad3 
phosphorylation. These ideas demonstrate that ALK1 opposes ALK5/TGF-β signalling in 
human chondrocytes similar to endothelial cells 79.  
 
 
5.4.3. The effect of ALK1 on cellular and extracellular collagen 
deposition 
Changes in mRNA expression do not always reflect the level of proteins 
production, or in the case of collagens and ECM, its deposition. In order to assess 
whether ALK1 can affect the process of lung fibrosis and collagen synthesis, further 
experiments were performed. From the presented results, ALK1 seems to be a player in 
fibroblast activation, although the mechanism of ALK1/ALK5 pathways was not specified 
yet. There were no obvious alterations in the cellular collagen production in HFL1 and 
IMR-90 cells, which could be ALK1-dependent (Figure 4.14.). Transforming growth factor 
β1-induced collagen production without any action of ALK1, and the attenuation of that 
production after siRNA knockdown of ALK1, were observed in HFL1 cells but not in   
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IMR-90. However, the changes occurred in the secretion of collagen by the IMR-90 cells 
into the culture media (Figure 4.15.). The ALK1 silencing displayed similar effects on 
collagen secretion, as was shown at the mRNA expression level of COL1A1 (Figure 
4.13.) in the same cell line. The significant decrease in collagen secretion after ablation of 
ALK1 was rescued by TGF-β1 stimulation. The HFL1 and IMR-90 cells differ from each 
other in that they have different origins, and they were isolated from different aged 
foetuses, which could explain the divergent results obtained with collagen deposition.  
The lack of ALK1 was associated with the fibrosis (Figure 4.3.) and seems to be 
involved in the activation of fibroblast (Figure 4.6.), but the details of such an action are 
not clear yet. The collagen deposition assay demonstrated that the lack of ALK1 leads to 
the decreased collagen production (Figure 4.15. and 4.16.), and more specifically to the 
decreased amount of COL1A1 mRNA (Figure 4.13). The opposite results could be 
explained by technical problems of the projects, as it has been mentioned that there is no 
information about the subjects from whom the lungs and primary fibroblasts were taken. 
Additionally, results were obtained with fibroblast cell lines, not primary cells, which could 
be the weak point of this study. The important point is that fibroblasts in the fibrotic lung 
tissue are constantly exposed to the action of TGF-β, which is a highly regulated 
profibrotic cytokine in IPF; therefore, cell culture of fibroblast cell lines without TGF-β 
does not reflect the fibrotic environment. Moreover, the data presented here were 
obtained in vitro, which perhaps can not be extrapolated to IPF in humans in vivo.  
To date, no report have demonstrated ALK1 expression and action in lung 
fibroblasts. Although, as mentioned previously 130, the TGF-βRI-dependent upregulation 
of collagen and connective tissue growth factor (CTGF), a profibrotic cytokine 
upregulated in various fibrotic diseases, does not involve Smad2/3 activation, but is 
mediated by ALK1/Smad1 and ERK1/2 pathways. The inhibition of ALK5 either by a 
chemical inhibitor or using the ALK5 mutant cells have not associated with Smad3 
phosphorylation, and potentially stimulated collagen protein levels. Furthermore, Smad1-
specific siRNA abolished elevated level of collagen type I and CTGF expression in this 
model, pointing to the importance of ALK1/Smad1 signalling in the regulation of the 
profibrotic gene program in this model of fibrosis. The authors 130 used the scleroderma 
as the fibrosis model and dermal fibroblast isolated from diseases areas of skin, which 
might be the major feature different from the lung fibrosis.  
Interestingly, recent studies have also demonstrated involvement of ALK1/Smad1 
pathways in kidney and liver fibrosis. Elevated expression of Smad1 protein was 
observed in the human diabetic kidney, and in animal model of diabetic nephropathy 169-
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171. In addition, Smad1 was shown to directly upregulate expression of the collagen type 
IV gene in mesangial cells 169. Similarly, TGF-β signaling via activation of the 
ALK1/Smad1 pathway and subsequent upregulation of Id1 gene has been shown to 
contribute to transdifferentiation of hepatic stellate cells into myofibroblasts. The Id1 
expression and Smad1 phosphorylation correlate with severity of bile duct ligation-
induced liver fibrosis 131. These recent studies strongly suggest that activation of 
ALK1/Smad1 may play an important role in development of organ fibrosis.  
Moreover, the authors 130 demonstrated that activation of ERK1/2 pathway, which 
plays a relatively small role in TGF-β-dependent CTGF stimulation in dermal fibroblasts, 
was required for adenoviral transfected TGF-βRI-dependent persistent phosphorylation of 
Smad1 and subsequent elevated level of CTGF and collagen mRNA 130. Similarly, 
activation of ERK1/2 was required for the phosphorylation of Smad1 in cardiomyocytes 
172. Moreover, concomitant activation of Smad1 and ERK1/2 pathways was observed in 
hepatic stellate cells in a bile duct ligation-induced liver fibrosis, suggesting that 
interaction between Smad1 and ERK pathways may be a general phenomenon 173.  
In conclusion, these reports provides evidence for the existence of an alternative 
TGF-β-dependent, Smad3-independent signalling pathway that may operate during 
chronic stages of organ fibrosis. Fibroblasts from Smad3 null mice also exhibit a 
compensatory increase in activated MAPK levels in response to TGF-β 174, thus raising 
the possibility of a similar Smad3-independent pathway functioning in vivo during wound 
healing in this mouse model.  
An altered ratio of TGF-β receptor subunits has also been observed in fibrotic 
diseases. Modulation of TGF-βRI/RII ratio take place in fibroblasts during wound healing 
processes 175. The changes in the TGF-β receptor levels, together with the information 
about the pathways involved in fibrotic processes, suggest that the modulation of      
TGF-βRI and RII ratio might represent a novel model of diversity of TGF-β signalling and 
its biological effects in the normal and pathological conditions. The ALK1/Smad1 pathway 
might be of interest for the future potential target for the antifibrotic therapy in the organ 
fibrosis.  
 
 
5.5. Conclusions and future perspectives 
Activin receptor-like kinase 1, predominantly expressed in the endothelial cells, is 
a TGF-β type I receptor involved in angiogenesis and new tube formation, together with 
the widely-expressed second TGF-β type I receptor, ALK5. In endothelial cells, these 
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receptors function in a well-organised and controlled pattern to keep the balance during 
angiogenesis. The ALK1 has been recently demonstrated to play a role during organ 
fibrosis. In this study, for the first time, has been shown that ALK1 is present in human 
fibroblasts, and ALK1/Smad1/5/8 signalling is active. As fibroblasts are the major cells 
involved in the development of IPF, the potential role of ALK1 could be to influence 
collagen synthesis by these cells. Today, the pathway reported to lead to the excessive 
ECM production is the ALK5/Smad2/3 pathway. However, a recent publication has 
specified the involvement of ALK1/Smad1 signalling in fibroblast activation and collagen 
synthesis.  
In this study, we hypothesised that expression of TGF-β system components are 
changed in the IPF, and the only changes were visible in the case of ALK1. ALK1 was 
downregulated in the lungs of fibrotic patients, as well as in the primary human fibroblasts 
isolated from such lungs. Additionally, siRNA-mediated silencing of ALK1 changed 
collagen deposition, as well as COL1A1 mRNA expression. To be able to specify the 
involvement of either ALK1 or ALK5 in the collagen synthesis, further experiments have 
to be performed. The knockdown of ALK5, or the inhibition of ALK5 by the commercially 
available inhibitors SB431542 and IN-1130, would give at least a partial answer to the 
question, if the collagen deposition were driven by ALK1 or ALK5 signalling pathway.  
The present study was performed generally in human lung fibroblast cell lines, 
HFL1 and IMR-90. To have better correlation with the pathogenesis of the IPF in 
humans, the ALK1/ALK5 balance and their role in fibroblast activation and collagen 
deposition in the primary human fibroblasts would be of importance. The ALK1 and ALK5 
are expressed in these cells, although TGF-β/BMP signalling activity was not studied in 
primary cells. The phosphorylation of Smads performed by immunoblotting is the best 
and easiest way to get the information about the activity of TGF-β. The TGF-β is one of 
the many other profibrotic mediators well-studied and most abundant in the fibrosis 
processes, and it is expressed by all the cells involved in this disease, so it might be 
possible to detect the active TGF-β signalling in the primary fibroblasts.  
Methods such as microdissection would be a useful tool to collect material from 
the fibroblast foci, the specific places, which are the hallmark of fibrosis, cumulating the 
activated myofibroblasts. Using this method would be very important to get fibroblasts 
exactly from the diseased areas of the lung, and be sure the phenotype of these cells 
would not change during cultivation and culturing. The obtained RNA and proteins would 
represent the most interesting panel of any changes between the healthy and fibrotic 
patients. 
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Activin receptor-like kinase 1 heterozygous mice are available. The homozygous 
mice die at embryonic day 9.5 due to the lack of formation of branching capillary network 
and the dilation of the blood vessels 86. The heterozygous mice are normal, and serves 
as a model of HHT type 2 176-179. The influence of ALK1 knockout on the lung phenotype 
and eventual involvement in the fibrotic processes has not yet been studied. However, 
there are publications demonstrating the correlation of HHT, and ALK1 and endoglin 
mutations, with the pulmonary hypertension 180, 181. To investigate the fibrotic processes, 
such activation of fibroblasts and their differentiation, and collagen deposition, in the 
ALK1 heterozygous mice would be of important value. 
As mentioned 130, 131, 158, ALK1 is involved in the upregulation of collagen type I 
independently of Smad2/3 and ALK5, but surprisingly, together with the ERK pathway. To 
be able to specify not only between ALK1 and ALK5 and the Smads involved in their 
signal transduction, but also between ALK1/Smad1 and the other pathways, which might 
be involved in the molecular mechanism of collagen deposition, further experiments must 
be done. It was shown that activation of the ERK1/2 (p44/42) MAPK pathway contributes 
to collagen upregulation in skin and lung fibroblasts from scleroderma patients 182, 183. 
Tools exist which could be helpful to study this part of the project, for example, the 
specific antibodies for the phosphorylated forms of the MAPK kinases, commercially 
available inhibitors of kinases, such as UO126, the specific inhibitor of MEK, which all 
together would be possible to evaluate the activation of MAPK kinase pathways. 
Furthermore, this would clarify whether manipulation of ALK1 activity in pulmonary 
fibrosis offers the intriguing possibility of interfering with the development of the disease. 
Reliable methods should be developed to target ALK1/Smad1 signalling function 
specifically in the lung, as a potential therapy for pulmonary fibrosis. 
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6. Appendix 
6.1. List of primers used for PCR amplification 
6.1.1. Quantitative RT-PCR 
 
Quantitative RT-PCR 
GeneBank™ 
Accession 
number 
Forward Primer  
(5-3) 
Reverse Primer  
(5-3) 
Annealing 
temperature 
(°C) 
Amplicon 
size (bp) 
ACVRL1 human 
NM_000020.2 
GTGGAGTGTGTGG
GAAAAGG 
TCATGTCTGAGGCC
ATGAAG 
60 181 
BMPRIA (ALK3) 
human 
NM_004329.2 
TTTATGGCACCCAA
GGAAAG 
TGGTATTCAAGGGC
ACATCA 
60 156 
BMPRIB (ALK6) 
human 
NM_001203.1 
GGTTGCCTGTGGT
CACTTCT 
CCTTTCTGTGCAGC
ATTCAA 
60 110 
BMPRII human 
NM_001204.5 
GAAGACTGTTGGG
ACCAGGA 
TTGCGTTCATTCTG
CTAGC 
60 149 
COL1A1 human 
NM_000088.2 
CCAGAAGAACTGGT
ACATCAGC 
CGCCATACTCGAAC
TGGAAT 
60 94 
ENG human 
NM_000118.1 
GTGACGGTGAAGG
TGGAACT 
GATCTGCATGTTGT
GGTTGG 
60 114 
ID1 human 
NM_181353.1 
GTGGTGCGCTGTC
TGTCTGA 
AGTAACAGCCGTTC
ATGTCG 
60 129 
PAI-1 human 
NM_000602.1 
GAGAAACCCAGCA
GCAGATT 
TGGTGCTGATCTCA
TCCTTG 
60 125 
PBGD human 
NM_000190.3 
CCCACGCGAATCA
CTCTCAT 
TGTCTGGTAACGGC
AATGCG 
60 69 
-SMA human 
NM_001613.1 
GAGAAGAGTTACGA
GTTGCCTG 
TGTTAGCATAGAGG
TCCTTCCTG 
60 180 
SMAD1 human 
NM_005900.2 
CAGTCTGTGAACCA
TGGATTTG 
TAACATCCTGGCGG
TGGTAT 
60 109 
SMAD2 human 
NM_005901.4 
GGAATTTGCTGCTC
TTCTGG 
TCTGCCTTCGGTAT
TCTGCT 
60 128 
SMAD3 human 
NM_005902.3 
CTGTGTGAGTTCGC
CTTCAA 
CGGGGAAGTTAGT
GTTTTCG 
60 181 
SMAD4 human 
NM_005359.3 
TCACAATGAGCTTG
CATTCC 
GGGTCCACGTATC
CATCAAC 
60 156 
SMAD5 human 
NM_001001419.
1 
AAATGTCCAGAAAT
CTGCCTCT 
TCCCAGTTATTCGG
GAGACT 
60 99 
SMAD8 human  
NM_005905.4 
ATTTGGCTCCAAGC
AGAAAG 
GCTGAGCTGGGGG
TTATATTC 
60 117 
TGFβRI (ALK5) 
human 
NM_004612.2 
CAGCTCTGGTTGGT
GTCAGA 
ATGTGAAGATGGG
CAAGACC 
60 131 
TGFβRII human 
NM_003242.5 
TTTTCCACCTGTGA
CAACCA 
GGAGGAGCAGCAT
CTTCCAG 
60 185 
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6.1.2. Semi-quantitative RT-PCR 
 
Semi-quantitative RT-PCR 
GeneBank™ 
Accession 
number 
Forward Primer  
(5-3) 
Reverse Primer  
(5-3) 
Annealing 
temperature 
(°C) 
Amplicon 
size (bp) 
ACVRL1 human 
NM_000020.2 
ATCGCCTCAGACAT
GACCTC 
TGATCCACACACAC
CACCTT 
56-60 560 
BMPRIA (ALK3) 
human 
NM_004329.2 
TACACAGGAAACAT
TACAA 
CTTTTAGTGATTCTC
CAAC 
60 628 
BMPRIB (ALK6) 
human 
NM_001203.1 
CAAGAAAGAGGATG
GTGAG 
ATAATCATAAAGGG
AACCA 
60 832 
BMPRII human 
NM_001204.5 
CTCGAATCCCCAGC
CCTGAA 
GCCGGGGCTCTTTT
GTTGAA 
56-61 525 
HSP70 human 
NM_006597.3 
TGTGTCTGCTTGGT
AGGAATGGTGGTA 
TTACCCGTCCCCGA
TTTGAAGAAC 
58 387 
-SMA human 
NM_001613.1 
GAGAAGAGTTACGA
GTTGCCTG 
TGTTAGCATAGAGG
TCCTTCCTG 
60 180 
SMAD1 human 
NM_005900.2 
GGAGACAGCTTTAT
TTCACCATATC 
CAATAGTTTTCCAG
AGGCAGATG 
58 1491 
SMAD2 human 
NM_001003652
.2 
GGGAGGTTCGATA
CAAGAGGCT 
GGACCACACACAAT
GCTATGACA 
58-60 1530 
SMAD3 human 
NM_005902.3 
AGCCATGTCGTCCA
TCCTG 
CTTCTTCCTTGACA
ACAATGGG 
59 1383 
SMAD4 human 
NM_005359.3 
TTCACTGTTTCCAA
AGGATCAAAA 
GTAGCCACCATCCT
GATAACGTTAAG 
58-59 1780 
SMAD5 human 
NM_001001419
.1 
CTGTTCTTTCGGTA
GCCACTGAC 
GCATTATGAAACAG
AAGATATGGGG 
58 1459 
TGFβRII human 
NM_003242.5 
GGAAGCTCATGGA
CTTCAGC 
CCCACTGTTAGCCA
GGTCAT 
56-60 632 
 
6.2. List of antibodies 
6.2.1. Primary antibodies 
 
Antibody 
Primary Host Dilution Company 
  Immunoblotting Immunohistochemistry  
anti--actin rabbit 1:1000  Cell Signaling 
anti-ALK1 goat  1:100 Santa Cruz  
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anti--SMA mouse  1:1500 Sigma-Aldrich 
anti-
Smad1/2/3 
mouse 1:1000  Santa Cruz 
anti-Smad2/3 mouse 1:1000  BD Biosciences 
anti-phospho 
Smad1/5/8 
rabbit 1:500  Cell Signaling 
anti-phospho 
Smad2 
rabbit 1:500  Cell Signaling 
anti-TGFβRI 
(ALK5) 
rabbit 1:500  Cell Signaling 
anti-TGFβRI 
(ALK5) 
rabbit  1:100 Santa Cruz  
 
6.2.2. Secondary antibodies 
 
Antibody 
Secondary Host 
Dilution 
Company 
Immunoblotting Immunohistochemistry 
Biotinylated 
anti-mouse 
IgG 
goat  Ready to use Invitrogen 
Biotinylated 
anti-goat IgG 
goat  Ready to use Invitrogen 
Biotinylated 
anti-rabbit 
IgG 
goat  Ready to use Invitrogen 
HRP-
conjugated 
anti-mouse 
IgG 
goat 1:3000  Pierce 
HRP-
conjugated 
anti-rabbit 
IgG 
goat 1:3000  Pierce 
 
6.3. Human siRNA sequences 
 
Gene name ON-TARGETplus SMARTpool siRNA (5´-3´) 
 
ACVRL1 (NM_000020) 
si#1 AGCCUAAAGUGAUUCAAA 
si#2 GAGCAGGGCGACACGAUGU 
si#3 GUCAAGAUCUUCUCCUCGA 
si#4 CGGGAGUGCUGGUACCCAA 
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TGFβRI (ALK5) (NM_004612 ) 
si#1 GAGAAGAACGUUCGUGGUU 
si#2 UGCGAGAACUAUUGUGUUA 
si#3 GACCACAGACAAAGUUAUA 
si#4 CGAGAUAGGCCGUUUGUAU 
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